0001493152-18-015783.txt : 20181113 0001493152-18-015783.hdr.sgml : 20181113 20181113170124 ACCESSION NUMBER: 0001493152-18-015783 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181113 DATE AS OF CHANGE: 20181113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CARDAX, INC. CENTRAL INDEX KEY: 0001544238 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454484428 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-181719 FILM NUMBER: 181178889 BUSINESS ADDRESS: STREET 1: 2800 WOODLAWN DRIVE STREET 2: SUITE 129 CITY: HONOLULU STATE: HI ZIP: 96822 BUSINESS PHONE: 808-457-1400 MAIL ADDRESS: STREET 1: 2800 WOODLAWN DRIVE STREET 2: SUITE 129 CITY: HONOLULU STATE: HI ZIP: 96822 FORMER COMPANY: FORMER CONFORMED NAME: Koffee Korner Inc. DATE OF NAME CHANGE: 20120308 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(MARK ONE)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to___________

Commission File No. 333-181719

CARDAX, INC.

(Exact name of registrant as specified in its charter)

Delaware		45-4484428
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

2800 Woodlawn Drive, Suite 129, Honolulu, Hawaii 96822

(Address of principal executive offices, zip code)

(808) 457-1400

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year,

if changed since last report)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (check one):

Large accelerated filer [ ]		Accelerated filer [ ]
Non-accelerated filer [ ] (Do not check if a smaller reporting company)		Smaller reporting company [X]
Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes [ ] No [X]

As of November 13, 2018, there were 133,338,573 shares of common stock, $0.001 par value per share (“Common Stock”), of the registrant outstanding.

TABLE OF CONTENTS

	Page
PART I. FINANCIAL INFORMATION	4
Item 1. Financial Statements.	4
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	24
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	28
Item 4. Controls and Procedures.	28

PART II. OTHER INFORMATION	29
Item 1. Legal Proceedings.	29
Item 1A. Risk Factors.	29
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3. Defaults Upon Senior Securities.	30
Item 4. Mine Safety Disclosures.	30
Item 5. Other Information.	30
Item 6. Exhibits.	30

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

There are statements in this quarterly report that are not historical facts. These “forward-looking statements” can be identified by use of terminology such as “anticipate,” “believe,” “estimate,” “expect,” “hope,” “intend,” “may,” “plan,” “positioned,” “project,” “propose,” “should,” “strategy,” “will,” or any similar expressions. You should be aware that these forward-looking statements are subject to risks and uncertainties that are beyond our control. Although we believe that our assumptions underlying such forward-looking statements are reasonable, we do not guarantee our future performance, and our actual results may differ materially from those contemplated by these forward-looking statements. Our assumptions used for the purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances, including the development, acceptance and sales of our products and our ability to raise additional funding sufficient to implement our strategy. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. In light of these numerous risks and uncertainties, we cannot provide any assurance that the results and events contemplated by our forward-looking statements contained in this quarterly report will in fact transpire. These forward-looking statements are not guarantees of future performance. You are cautioned to not place undue reliance on these forward-looking statements, which speak only as of their dates. We do not undertake any obligation to update or revise any forward-looking statements.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

Condensed Consolidated Financial Statements

Cardax, Inc., and Subsidiary

September 30, 2018 and 2017

Contents

	Page

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS:

Condensed consolidated balance sheets	5

Condensed consolidated statements of operations	6

Condensed consolidated statements of cash flows	7

Notes to the condensed consolidated financial statements	8

Cardax, Inc., and Subsidiary

CONDENSED CONSOLIDATED BALANCE SHEETS

As of

	September 30,			December 31,
	2018			2017
	(Unaudited)
ASSETS
CURRENT ASSETS
Cash	$	198,574		$	2,236,837
Accounts receivable		452,225			37,243
Inventories		326,174			340,425
Deposits and other assets		119,066			90,831
Prepaid expenses		24,052			22,838

Total current assets		1,120,091			2,728,174

PROPERTY AND EQUIPMENT, net		-			1,901

INTANGIBLE ASSETS, net		435,141			426,610

TOTAL ASSETS	$	1,555,232		$	3,156,685

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
Accrued payroll and payroll related expenses, current portion	$	3,450,570		$	3,404,610
Accounts payable and accrued expenses		875,957			603,391
Fees payable to directors		418,546			418,546
Employee settlement		50,000			50,000

Total current liabilities		4,795,073			4,562,162

ACCRUED PAYROLL AND PAYROLL RELATED EXPENSES, net of current portion		94,885			85,615

COMMITMENTS AND CONTINGENCIES		-			-

Total liabilities		4,889,958			4,647,777

STOCKHOLDERS’ DEFICIT
Preferred Stock - $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2018, and December 31, 2017, respectively		-			-
Common stock - $0.001 par value; 400,000,000 shares authorized, 133,338,573 and 122,674,516 shares issued and outstanding as of September 30, 2018, and December 31, 2017, respectively		133,339			122,675
Additional paid-in-capital		58,067,566			56,401,069
Subscriptions receivable		(539,662	)		-
Deferred compensation		-			(10,125	)
Accumulated deficit		(60,995,969	)		(57,919,096	)

Total stockholders’ deficit		(3,334,726	)		(1,405,477	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	1,555,232		$	3,156,685

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

Cardax, Inc., and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the three-months ended September 30,						For the nine-months ended September 30,
	2018			2017			2018			2017
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
REVENUES, net	$	549,540		$	321,861		$	1,134,899		$	496,088

COST OF GOODS SOLD		240,152			149,207			521,353			222,056

GROSS PROFIT		309,388			172,654			613,546			274,032

OPERATING EXPENSES:
Salaries and wages		387,119			129,670			1,202,576			451,351
Selling, general, and administrative expenses		350,630			213,538			1,168,747			492,895
Professional fees		225,875			124,769			637,042			299,569
Stock based compensation		180,562			58,250			443,249			142,500
Research and development		86,115			1,798			214,093			74,215
Depreciation and amortization		6,718			7,388			23,853			22,189

Total operating expenses		1,237,019			535,413			3,689,560			1,482,719

Loss from operations		(927,631	)		(362,759	)		(3,076,014	)		(1,208,687	)

OTHER INCOME (EXPENSES):
Other income		-			-			556			12,598
Interest income		7			676			1,941			1,844
Interest expense		(1,264	)		(1,073	)		(3,356	)		(2,790	)

Total other (expenses) income, net		(1,257	)		(397	)		(859	)		11,652

Loss before the provision for income taxes		(928,888	)		(363,156	)		(3,076,873	)		(1,197,035	)

PROVISION FOR INCOME TAXES		-			-			-			-

NET LOSS	$	(928,888	)	$	(363,156	)	$	(3,076,873	)	$	(1,197,035	)

NET LOSS PER SHARE
Basic	$	(0.01	)	$	(0.00	)	$	(0.02	)	$	(0.01	)
Diluted	$	(0.01	)	$	(0.00	)	$	(0.02	)	$	(0.01	)

SHARES USED IN CALCULATION OF NET LOSS PER SHARE
Basic		130,083,598			100,587,843			125,271,516			92,513,317
Diluted		130,083,598			100,587,843			125,271,516			92,513,317

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

Cardax, Inc., and Subsidiary

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the nine-months ended September 30,

	2018			2017
	(Unaudited)			(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,076,873	)	$	(1,197,035	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		23,853			22,189
Stock based compensation		443,249			142,500
Bad debt expense on note receivable and accrued interest		89,933			-
Changes in assets and liabilities:
Accounts receivable		(193,168	)		(276,303	)
Inventories		14,251			(43,963	)
Deposits and other assets		(118,168	)		(74,850	)
Prepaid expenses		(1,214	)		(229	)
Accrued payroll and payroll related expenses		55,230			(25,720	)
Accounts payable and accrued expenses		50,752			55,979

Net cash used in operating activities		(2,712,155	)		(1,397,432	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in intangible assets		(30,483	)		(16,137	)

Net cash used in investing activities		(30,483	)		(16,137	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of common stock		704,375			4,013,456
Proceeds from the exercise of warrants		-			40,000

Net cash provided by financing activities		704,375			4,053,456

NET DECREASE (INCREASE) IN CASH		(2,038,263	)		2,639,887

CASH AT THE BEGINNING OF THE PERIOD		2,236,837			158,433

CASH AT THE END OF THE PERIOD	$	198,574		$	2,798,320


SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	$	3,356		$	2,790
Cash paid for income taxes	$	-		$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of accounts payable into restricted stock	$	-		$	44,700
Settlement of receivables with payables	$	221,814		$	-
Subscription receivable recognized for common shares issued	$	539,662		$	-

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

NOTE 1 – COMPANY BACKGROUND

Cardax Pharmaceuticals, Inc. (“Holdings”) was incorporated in the State of Delaware on March 23, 2006.

Holdings was formed for the purpose of developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play important causative roles. Holdings’ platform has application in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. Holdings’ current primary focus is on the development of astaxanthin technologies. Astaxanthin is a naturally occurring marine compound that has robust anti-oxidant and anti-inflammatory activity.

In May of 2013, Holdings formed a 100% owned subsidiary company called Cardax Pharma, Inc. (“Pharma”). Pharma was formed to maintain Holdings’ operations going forward, leaving Holdings as an investment holding company.

On November 29, 2013, Holdings entered into a definitive merger agreement (“Merger Agreement”) with Koffee Korner Inc., a Delaware corporation (“Koffee Korner”) (OTCQB:KOFF), and its wholly owned subsidiary (“Koffee Sub”), pursuant to which, among other matters and subject to the conditions set forth in such Merger Agreement, Koffee Sub would merge with and into Pharma. In connection with such merger agreement and related agreements, upon the consummation of such merger, Pharma would become a wholly owned subsidiary of Koffee Korner and Koffee Korner would issue shares of its common stock to Holdings. At the effective time of such merger, Holdings would own a majority of the shares of the then issued and outstanding shares of common stock of Koffee Korner.

On February 7, 2014, Holdings completed its merger with Koffee Korner, which was renamed to Cardax, Inc. (the “Company”) (OTCQB:CDXI). Concurrent with the merger: (i) the Company received aggregate gross cash proceeds of $3,923,100 in exchange for the issuance and sale of an aggregate 6,276,960 of shares of the Company’s common stock, together with five year warrants to purchase an aggregate of 6,276,960 shares of the Company’s common stock at $0.625 per share, (ii) the notes issued on January 3, 2014, in the outstanding principal amount of $2,076,000 and all accrued interest thereon, automatically converted into 3,353,437 shares of the Company’s common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 3,321,600 shares of common stock at $0.625 per share, (iii) the notes issued in 2013, in the outstanding principal amount of $8,489,036 and all accrued interest thereon, automatically converted into 14,446,777 shares of the Company’s common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 14,446,777 shares of common stock at $0.625 per share, (iv) stock options to purchase 15,290,486 shares of Holdings common stock at $0.07 per share were cancelled and substituted with stock options to purchase 6,889,555 shares of the Company’s common stock at $0.155 per share, (v) additional stock options to purchase 20,867,266 shares of the Company’s common stock at $0.625 per share were issued, and (vi) the notes issued in 2008 and 2009, in the outstanding principal amounts of $55,000 and $500,000, respectively, and all accrued interest thereon, were repaid in full. The assets and liabilities of Koffee Korner were distributed in accordance with the terms of a spin-off agreement on the closing date.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 1 – COMPANY BACKGROUND (continued)

The share exchange transaction was treated as a reverse acquisition, with Holdings and Pharma as the acquirers and Koffee Korner and Koffee Sub as the acquired parties. Unless the context suggests otherwise, when the Company refers to business and financial information for periods prior to the consummation of the reverse acquisition, the Company is referring to the business and financial information of Holdings and Pharma. Under accounting principles generally accepted in the United States of America (“U.S. GAAP”) guidance Accounting Standards Codification (“ASC”) No. 805-40, Business Combinations – Reverse Acquisitions, the Acquisition has been treated as a reverse acquisition with no adjustment to the historical book and tax basis of the Company’s assets and liabilities.

On August 28, 2014, the Company entered into an Agreement and Plan of Merger (the “Holdings Merger Agreement”) with its principal stockholder, Holdings, pursuant to which Holdings would merge with and into the Company (the “Holdings Merger”). On September 18, 2015, the Company filed a Form S-4 with the SEC in contemplation of the Holdings Merger. There would not be any cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the stockholders of Holdings would receive an aggregate number of shares and warrants to purchase shares of the Company’s common stock equal to the aggregate number of shares of the Company’s common stock that were held by Holdings on the date of the closing of the Holdings Merger. The Company’s restricted shares of common stock held by Holdings would be cancelled upon the closing of the Holdings Merger. Accordingly, there would not be not any change to the Company’s fully diluted capitalization due to the Holdings Merger.

On November 24, 2015, the Holdings Merger Agreement was amended and restated (the “Amended Holdings Merger Agreement”). Under the terms of Amended Holdings Merger Agreement, the shares of common stock, par value $0.001 per share of Holdings and the shares of all other issued and outstanding capital stock of Holdings that by their terms were convertible or could otherwise be exchanged for shares of Holdings common stock, would be converted into and exchanged for the Company’s shares of Common Stock in a ratio of approximately 2.2:1. In addition, the Company would grant Holdings’ option and warrant holders warrants to purchase the Company’s warrants at the same stock conversion ratio. On November 24, 2015, the Company filed an amendment to the Form S-4 with the SEC and on March 29, 2015, the Form S-4 was declared effective by the SEC.

On December 30, 2015, the Company completed its merger with Holdings, pursuant to the Amended Holdings Merger Agreement. At closing, Holdings merged with and into the Company, with the Company surviving the Holdings Merger. Pursuant to the Amended Holdings Merger Agreement, there was not any cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the stockholders of Holdings received an aggregate number of shares and warrants to purchase shares of Company common stock equal to the aggregate number of shares of Company common stock that were held by Holdings on the date of the closing of the Holdings Merger. The Company’s restricted shares of common stock held by Holdings were cancelled upon the closing of the Holdings Merger. Accordingly, there was not any change to the Company’s fully diluted capitalization due to the Holdings Merger.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 1 – COMPANY BACKGROUND (continued)

The Company is engaged in the development and commercialization of dietary supplements and pharmaceuticals. The Company’s first commercial product, ZanthoSyn®, is a physician recommended anti-inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The Company sells ZanthoSyn® primarily through wholesale and e-commerce channels. The Company is also developing astaxanthin and related compounds, including CDX-085, for pharmaceutical applications. The safety and efficacy of the Company’s products have not been directly evaluated in clinical trials or confirmed by the FDA.

Going concern matters

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred net losses of $928,888 and $3,076,873, for the three and nine-months ended September 30, 2018, respectively, and net losses of $363,156 and $1,197,035 for the three and nine-months ended September 30, 2017, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $60,995,969 as of September 30, 2018, and has had negative cash flows from operating activities since inception. The Company expects that its marketing program for ZanthoSyn® will continue to focus on outreach to physicians, healthcare professionals, retail personnel, and consumers, and anticipates further losses in the development of its business. As a result of these and other factors, management has determined there is substantial doubt about the Company’s ability to continue as a going concern.

During the quarter ended September 30, 2018, the Company raised additional capital to carry out its business plan. As part of the Company’s efforts, it raised an additional $1.44 million in gross proceeds through the exchange of 9.6 million warrants via a warrant exchange offering that closed on July 27, 2018. As of September 30, 2018, $653,278 of this amount remained in an escrow account as subscriptions receivable and was collected on October 5, 2018, less $113,616 in placement fees and expenses, to net $539,662.

The Company’s continued ability to raise additional capital through future equity and debt securities issuances is unknown. Obtaining additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Unaudited interim financial information

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2018 and 2017.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Unaudited interim financial information (continued)

Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC.

These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on March 27, 2018.

Revenue from contracts with customers

In May 2014, the Financial Accounting Standards Board (“FASB”) issued a new standard related to revenue recognition. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.

The Company adopted this standard effective January 1, 2018, using the retrospective method. As there was no impact on contracts that were previously completed and no significant impact to contracts completed after adoption, there was no need to restate prior results from operations.

The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration.

The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended:

		September 30, 2018		September 30, 2017
Geographical area	Source	(Unaudited)		(Unaudited)
United States	Nutraceuticals	$	1,118,486	$	496,088
Hong Kong	Nutraceuticals	$	16,413	$	-

Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale.

Other significant accounting policies

There have been no other material changes to our significant accounting policies during the nine-months ended September 30, 2018, as compared to the significant accounting policies described in our Annual Report.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Recently issued accounting pronouncements not yet adopted

In February 2016, the FASB issued ASU No. 2016-02, Leases. This ASU requires management to recognize lease assets and lease liabilities for all leases. ASU No. 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous lease guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The guidance in ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently assessing the impact of this ASU on the Company’s condensed consolidated financial statements.

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent accounting for employee share-based compensation. The guidance in ASU No. 2018-07 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018. The Company is currently in the process of evaluating the impact of the adoption of this ASU on its condensed consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the FASB’s Concepts Statement, including the consideration of costs and benefits. The guidance in ASU No. 2018-13 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019. The Company is currently in the process of evaluating the impact of the adoption of this ASU on its condensed consolidated financial statements.

Recently adopted accounting pronouncements

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 23). The amendments of ASU No. 2017-18 require that a statement of cash flow explain the change during a period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The guidance of ASU No. 2016-18 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company has assessed the impact of this ASU and does not believe that this update has a significant impact on its condensed consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation: Scope of Modification Accounting. The amendments of ASU No. 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance of ASU No. 2017-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company has assessed the impact of this ASU and does not believe that this update has a significant impact on its condensed consolidated financial statements.

The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the condensed consolidated financial statements.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Reclassifications

The Company has made certain reclassifications to conform its prior periods’ data to the current presentation, such as reclassifying a separation agreement that has terms extending beyond one year. These reclassifications had no effect on the reported results of operations or cash flows.

NOTE 3 – INVENTORIES

Inventories consist of the following as of:

	September 30, 2018 (Unaudited)		December 31, 2017
Finished goods	$	267,543	$	240,917
Raw materials		58,631		98,937
Packing supplies and materials		-		571
Total inventories	$	326,174	$	340,425

NOTE 4 – PROPERTY AND EQUIPMENT, net

Property and equipment, net, consists of the following as of:

	September 30, 2018 (Unaudited)		December 31, 2017
Information technology equipment	$	-	$	31,892
Less accumulated depreciation		-		(29,991	)
Total property and equipment, net	$	-	$	1,901

Depreciation expense was $0 and $1,901, for the three and nine-months ended September 30, 2018, respectively, and $1,496 and $4,513, for the three and nine-months ended September 30, 2017, respectively.

During the nine-months ended September 30, 2018, Company wrote off its fully depreciated equipment. There was no gain or loss recognized for this write-off.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 5 – INTANGIBLE ASSETS, net

Intangible assets, net, consists of the following as of:

	September 30, 2018 (Unaudited)			December 31, 2017
Patents	$	522,575		$	493,027
Less accumulated amortization		(285,795	)		(263,843	)
		236,780			229,184
Patents pending		198,361			197,426
Total intangible assets, net	$	435,141		$	426,610

Patents are amortized straight-line over a period of fifteen years. Amortization expense was $6,717 and $21,952 for the three and nine-months ended September 30, 2018, respectively, and $5,892 and $17,676 for the three and nine-months ended September 30, 2017, respectively.

The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved.

The Company owns 25 issued patents, including 14 in the United States and 11 others in Europe, Canada, China, India, Japan, and Hong Kong. These patents will expire beginning in 2023 through 2028, subject to any patent term extensions of the individual patent. The Company has 3 foreign patent applications pending in Europe and Brazil.

NOTE 6 –ACCRUED SEPARATION COSTS

On August 9, 2016, the Company entered into a separation agreement with an employee to pay $118,635 of accrued compensation over nine-years. This amount is included in accrued payroll and payroll related expenses in the accompanying balance sheets. This amount does not yield interest and matures as follows for the twelve-months ended September 30:

2019	$	9,000
2020		9,000
2021		11,250
2022		12,000
2023		16,500
Thereafter		46,135
		103,885
Less current portion		(9,000	)
	$	94,885

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 7 – STOCKHOLDERS’ DEFICIT

Warrant exchange

In June 2018, the Company commenced an offering to exchange outstanding warrants for shares of common stock under a Form S-4 Registration Statement. These shares of common stock would be issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of common stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants for $1,440,043 in gross proceeds and 9,600,286 shares of common stock. Of this amount, $653,278 was held in escrow as subscriptions receivable as of September 30, 2018 and received on October 5, 2018, less $113,616 in placement fees and expenses, to net $539,662.

Self-directed stock issuance

During the year ended December 31, 2017, the Company sold securities in a self-directed offering in the aggregate amount of $179,000, $3,774,456, and $124,979 at $0.08, $0.12, and $0.30, respectively, per unit. Each $0.08 unit consisted of 1 share of restricted common stock (2,237,500 shares), a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.08 per share, a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.12 per share, and a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.16 per share. Each $0.12 unit consisted of 1 share of restricted common stock (31,453,788 shares) and a five-year warrant to purchase 1 share of restricted common stock (31,453,788 warrant shares) at $0.12 per share. Each $0.30 unit consisted of 1 share of restricted common stock (416,595 shares) and a five-year warrant to purchase 1 share of restricted common stock (416,595 warrant shares) at $0.30 per share.

Equity purchase agreement

In July 2016, the Company entered into an equity purchase agreement (the “EPA”) and a registration rights agreement with an investor. Pursuant to the terms of the EPA, the Company has the right, but not the obligation, to sell shares of its common stock to the investor on the terms specified in the EPA. On the date of the EPA, the Company issued 1,500,000 shares to the investor. The total fair value of this stock on the date of grant was $106,500. These shares were fully vested upon issuance.

During the nine-months ended September 30, 2018 and 2017, the Company sold 0 and 567,644 shares of common stock for $0 and $60,000, respectively, pursuant to the EPA.

Payable settlement

In May 2017, the Company settled a payable in the amount of $44,700 with a previously engaged broker dealer through the issuance of securities at $0.08 per unit. Each unit consisted of 1 share of restricted common stock (558,750 shares), a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.08 per share, a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.16 per share.

Shares outstanding

As of September 30, 2018 and December 31, 2017, the Company had a total of 133,338,573 and 122,674,516, respectively, shares of common stock outstanding.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 8 – STOCK GRANTS

Director stock grants

During the nine-months ended September 30, 2018 and 2017, the Company granted its independent directors an aggregate of 906,774 and 418,025 shares of restricted common stock in the Company, respectively. These shares were fully vested upon issuance. The increase in number of shares issued was due to the expansion of the Board of Directors by two members in June 2018. The total fair value of this stock on the date of grant was $200,000 and $93,750 for the nine-months ended September 30, 2018 and 2017, respectively.

Consultant stock grants

On April 10, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.23 per share. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on April 1, 2017. The Company recognized $5,750 and $11,500 in stock based compensation related to this grant during the nine-months ended September 30, 2018 and 2017, respectively.

On August 8, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.175 per share. These shares were subject to a risk of forfeiture and vested 25% upon grant and quarterly in arrears thereafter commencing on September 1, 2017. The Company recognized $4,375 and $8,750 in stock based compensation related to this grant during the nine-months ended September 30, 2018 and 2017, respectively.

NOTE 9 – STOCK OPTION PLANS

On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares that could be issued under this plan upon adoption was 30,420,148. On April 16, 2015, the majority stockholder of the Company approved an increase in the Company’s 2014 Equity Compensation Plan by 15 million shares.

Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 9 – STOCK OPTION PLANS (continued)

A summary of stock option activity is as follows:

	Options			Weighted average exercise price		Weighted average remaining contractual term in years		Aggregate intrinsic value
Outstanding January 1, 2017		36,821,969		$	0.41		5.94	$	301,273
Exercisable January 1, 2017		36,771,969		$	0.41		5.94	$	299,273
Canceled		-
Granted		2,161,458
Exercised		(770,000	)		-
Forfeited		-
Outstanding December 31, 2017		38,213,427		$	0.41		5.23	$	562,456
Exercisable December 31, 2017		36,213,427		$	0.41		4.98	$	562,456
Canceled		(350,000	)
Granted		1,833,334
Exercised		(156,997	)		-
Forfeited		(43,003	)
Outstanding September 30, 2018		39,496,761		$	0.41		4.64	$	986,808
Exercisable September 30, 2018		36,580,097		$	0.41		4.28	$	963,475

The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on September 30, 2018, based on a valuation of the Company’s stock for that day.

A summary of the Company’s non-vested options for the year ended December 31, 2017, and nine-months ended September 30, 2018, are presented below:

Non-vested at January 1, 2017	50,000
Granted	2,161,458
Vested	(211,458	)
Canceled	-
Non-vested at December 31, 2017	2,000,000
Granted	1,833,334
Vested	(566,670	)
Canceled	(350,000	)
Non-vested at September 30, 2018	2,916,664

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 9 – STOCK OPTION PLANS (continued)

The Company estimates the fair value of stock options granted on each grant date using the Black-Scholes option valuation model and recognizes an expense ratably over the requisite service period. The range of fair value assumptions related to options issued were as follows for the:

	Nine-months ended September 30, 2018			Year ended December 31, 2017
Dividend yield		0.0	%		0.0	%
Risk-free rate		2.38% - 2.80	%		1.89% - 2.26	%
Expected volatility		217% - 226	%		221% - 232	%
Expected term		3 - 7 years			5 - 7 years

The expected volatility was calculated based on the historical volatility of the Company. The risk-free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected dividend yield was zero, because the Company does not anticipate paying a dividend within the relevant timeframe. Due to a lack of historical information needed to estimate the Company’s expected term, it was estimated using the simplified method allowed.

The Company records forfeitures as they occur and reverses compensation cost previously recognized, in the period the award is forfeited, for an award that is forfeited before completion of the requisite service period.

Stock option exercise

During the nine-months ended September 30, 2018, the Company issued 156,997 shares of common stock in connection with the cashless exercise of stock options for 100,000, 50,000, and 50,000 shares of common stock exercisable at $0.06 per share with 43,003 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.

During the year ended December 31, 2017, the Company issued 645,288 shares of common stock in connection with the cashless exercise of stock options for 100,000, 45,000, and 625,000 shares of common stock exercisable at $0.155, $0.06, and $0.06, respectively, per share with 124,712 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 9 – STOCK OPTION PLANS (continued)

Stock based compensation

The Company recognized stock-based compensation expense related to options during the:

	Nine-months ended September 30
	2018				2017
	Number		Amount		Number		Amount

Employee compensation		450,000	$	156,875		-	$	-
Compensation for outside services		375,000		76,250		50,000		3,500
Director compensation		-		-		161,458		25,000

Total		825,000	$	233,125		211,458	$	28,500

NOTE 10 – WARRANTS

The following is a summary of the Company’s warrant activity:

	Warrants			Weighted average exercise price		Weighted average remaining contractual term in years		Aggregate intrinsic value
Outstanding January 1, 2017		88,365,036		$	0.30		3.50	$	543,770
Exercisable January 1, 2017		88,365,036		$	0.30		3.50	$	543,770
Canceled		-
Granted		40,259,133
Exercised		(798,000	)
Forfeited		(392,047	)
Outstanding December 31, 2017		127,434,122		$	0.24		3.15	$	3,957,689
Exercisable December 31, 2017		127,434,122		$	0.24		3.15	$	3,957,689
Canceled		-
Granted		315,010
Exercised		9,600,286
Forfeited		-
Outstanding September 30, 2018		118,148,846		$	0.20		2.57	$	7,848,637
Exercisable September 30, 2018		118,148,846		$	0.20		2.57	$	7,848,637

The Company estimates the fair value of warrants granted on each grant date using the Black-Scholes option valuation model. The expected volatility is calculated based on the historical volatility of the Company. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the warrants to be valued. The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. Due to a lack of historical information needed to estimate the Company’s expected term, it is estimated using the simplified method allowed.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 10 – WARRANTS (continued)

The Company did not recognize any stock-based compensation expense related to warrants during the nine-months ended September 30, 2018 and 2017, respectively.

Warrant exercise

During the year ended December 31, 2017, the Company issued 233,217 shares of common stock in connection with the cashless exercise of a warrant for 298,000 shares of common stock at $0.10 per share with 64,783 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.

During the year ended December 31, 2017, the Company issued 500,000 shares of common stock in connection with the exercise of a warrant for 500,000 shares of common stock at $0.08 per share in exchange for $40,000.

Warrant expiration

During the year ended December 31, 2017, warrants to purchase an aggregate of 392,047 shares of restricted common stock expired.

Warrant exchange

In June 2018, the Company commenced an offering to exchange outstanding warrants for shares of common stock under a Form S-4 Registration Statement. These shares of common stock would be issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of common stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants for $1,440,043 in gross proceeds and 9,600,286 shares of common stock. Of this amount, $653,278 was held in escrow as subscriptions receivable as of September 30, 2018. The subscriptions receivable amount was received on October 5, 2018, less $113,616 in placement fees and expenses, to net $539,662. As part of this exchange, warrants to purchase 315,010 shares of common stock at $0.21 per share were issued to investment bankers for their services.

NOTE 11 – INCOME TAXES

The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed.

The effective tax rate for the three and nine-months ended September 30, 2018 and 2017, differs from the statutory rate of 21% as a result of state taxes (net of Federal benefit), permanent differences, and a reserve against deferred tax assets.

The Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes, which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. Based on the available objective evidence and the Company’s history of losses, management provides no assurance that the net deferred tax assets will be realized. As of September 30, 2018 and December 31, 2017, the Company has applied a valuation allowance against its deferred tax assets net of the expected income from the reversal of the deferred tax liabilities.

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 11 – INCOME TAXES

Recent tax legislation

On March 22, 2018, the Tax Cuts and Jobs Act (“TCJA”) was enacted into law, which significantly changes existing U.S. tax law and includes numerous provisions that affect our business, such as reducing the U.S. federal statutory tax rate from 35% to 21% effective January 1, 2018.

Uncertain tax positions

The Company is subject to taxation in the United States and two state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes.

Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events.

As of September 30, 2018 and December 31, 2017, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its condensed consolidated statements of operations, which is consistent with the recognition of these items in prior reporting periods.

The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed.

NOTE 12 – BASIC AND DILUTED NET LOSS PER SHARE

The following table sets forth the computation of the Company’s basic and diluted net loss per share for:

	Three-months ended September 30, 2018 (Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(928,888	)		130,083,598	$	(0.01	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(928,888	)		130,083,598	$	(0.01	)

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 12 – BASIC AND DILUTED NET LOSS PER SHARE (continued)

	Three-months ended September 30, 2017(Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(363,156	)		100,587,843	$	(0.00	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(363,156	)		100,587,843	$	(0.00	)

	Nine-months ended September 30, 2018 (Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(3,076,873	)		125,271,516	$	(0.02	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(3,076,873	)		125,271,516	$	(0.02	)

	Nine-months ended September 30, 2017 (Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(1,197,035	)		92,513,317	$	(0.01	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(1,197,035	)		92,513,317	$	(0.01	)

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended:

	September 30, 2018		September 30, 2017
	(Unaudited)		(Unaudited)
Common stock options		39,496,761		36,838,427
Common stock warrants		118,148,846		127,018,546
Total common stock equivalents		157,645,607		163,856,973

Cardax, Inc., and Subsidiary

NOTES TO THE CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS (continued)

NOTE 13 – LEASES

Manoa Innovation Center

The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $8,760 and $29,662, for the three and nine-months ended September 30, 2018, respectively, and $8,164 and $23,935, for the three and nine-months ended September 30, 2017, respectively.

Fleet Lease

In January 2018, the Company entered into a vehicle lease arrangement with a rental company for three vehicles. The terms of the leases require total monthly payments of $1,619 for three years. These leases convert to month-to-month leases in January 2021 unless terminated. Total rent expense under this agreement was $5,602 and $14,953, for the three and nine-months ended September 30, 2018, respectively, and $0 for the three and nine-months ended September 30, 2017.

NOTE 14 – SUBSEQUENT EVENTS

The Company evaluated all material events through the date the financials were ready for issuance. On October 5, 2018, the Company received the subscriptions receivable amount outstanding of $653,278, less $113,616 in placement fees and expenses, to net $539,662.

***

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Explanatory Note

Unless otherwise noted, references in this Form 10-Q to “Cardax,” the “Company,” “we,” “our” or “us” means Cardax, Inc., the registrant, and, unless the context otherwise requires, together with its wholly-owned subsidiary, Cardax Pharma, Inc., a Delaware corporation (“Pharma”), and Pharma’s predecessor, Cardax Pharmaceuticals, Inc., a Delaware corporation (“Holdings”), which merged with and into Cardax, Inc.

Corporate Overview and History

We acquired Cardax Pharma, Inc. (“Pharma”) and its life science business through the merger of Cardax Acquisition, Inc. (“Cardax Sub”), our wholly-owned transitory subsidiary (“Cardax Sub”), with and into Pharma on February 7, 2014 (the “Merger”), and a stock purchase agreement. As a result of these transactions, Pharma became our wholly-owned subsidiary. The only consideration that we paid under the stock purchase agreement and the Merger was shares of our Common Stock. On May 31, 2013, Pharma acquired all of the assets and assumed all of the liabilities of Cardax Pharmaceuticals, Inc. (“Holdings”). Accordingly, we have two predecessors: Pharma and Pharma’s predecessor, Holdings. Prior to the February 7, 2014 effective date of the Merger, we operated under the name “Koffee Korner Inc.” and our business was limited to a single location retailer of specialty coffee located in Houston, Texas. On the effective date of the Merger, we divested our coffee business and now exclusively continue Pharma’s life sciences business. On December 30, 2015, our former principal stockholder, Holdings, merged with and into us (the “Holdings Merger”). There was not any cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the stockholders of Holdings received an aggregate number of shares and warrants to purchase shares of our Common Stock equal to the aggregate number of shares of our Common Stock that were held by Holdings on the date of the closing of the Holdings Merger. Our restricted shares of our Common Stock held by Holdings were cancelled upon the closing of the Holdings Merger. Accordingly, there was not any change to our fully diluted capitalization due to the Holdings Merger.

We are devoting substantially all of our present efforts to establishing our business related to the development and commercialization of dietary supplements and pharmaceuticals. Our first commercial product, ZanthoSyn®, is a physician recommended anti-inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The form of astaxanthin utilized in ZanthoSyn® has demonstrated excellent safety in peer-reviewed published studies and is designated as GRAS (Generally Recognized as Safe) according to FDA regulations. We sell ZanthoSyn® primarily through wholesale and e-commerce channels and expect that our marketing program will continue to focus on education of physicians, healthcare professionals, retail personnel, and consumers. We are also developing astaxanthin and related compounds, including CDX-085, for pharmaceutical applications. The safety and efficacy of our products have not been directly evaluated in clinical trials or confirmed by the FDA.

Our financial statements have been prepared assuming that we will continue as a going concern; however, given our recurring losses from operations, our independent registered public accounting firm has determined there is substantial doubt about our ability to continue as a going concern.

Subsequent Events

On October 5, 2018, the Company received the subscriptions receivable amount outstanding of $653,278, less $113,616 in placement fees and expenses, to net $539,662.

Results of Operations

Results of Operations for the Three and Nine-Months Ended September 30, 2018 and 2017:

The following table reflects our operating results for the three and nine-months ended September 30, 2018 and 2017:

Operating Summary	Three-months ended September 30, 2018			Three-months ended September 30, 2017			Nine-months ended September 30, 2018			Nine-months ended September 30, 2017
Revenues	$	549,540		$	321,861		$	1,134,899		$	496,088
Cost of Goods Sold		(240,152	)		(149,207	)		(521,353	)		(222,056	)
Gross Profit		309,388			172,654			613,546			274,032
Operating Expenses		(1,237,019	)		(535,413	)		(3,689,560	)		(1,482,719	)
Net Operating Loss		(927,631	)		(362,759	)		(3,076,014	)		(1,208,687	)
Other (Loss) Income		(1,257	)		(397	)		(859	)		11,652
Net Loss	$	(928,888	)	$	(363,156	)	$	(3,076,873	)	$	(1,197,035	)

Operating Summary for the Three-Months Ended September 30, 2018 and 2017

We sell ZanthoSyn® primarily through wholesale and e-commerce channels. We launched our e-commerce channel in August 2016 and began selling to GNC stores in Hawaii on January 25, 2017 and GNC corporate stores across the United States on August 10, 2017. As a result, revenues were $549,540 and $321,861 for the three-months ended September 30, 2018 and 2017, respectively. Costs of goods sold were $240,152 and $149,207 for the three-months ended September 30, 2018 and 2017, respectively, and included costs of the product, shipping and handling, sales taxes, merchant fees, and other costs incurred on the sale of goods. Gross profits were $309,388 and $172,654 for the three-months ended September 30, 2018 and 2017, respectively, which represented gross profit margins of approximately 56% and 54%, respectively.

Operating expenses were $1,237,019 and $535,413 for the three-months ended September 30, 2018 and 2017, respectively. The increase in operating expenses was primarily due to (i) sales and marketing personnel and related activities, (ii) partial restoration of employee salaries, (iii) stock-based compensation for new employees and directors, (iv) initiation of a clinical trial, and (v) pharmaceutical development efforts. Operating expenses primarily consisted of expenses for services provided to the Company, including payroll and consultation, for research and development, administration, and sales and marketing. These expenses were paid in accordance with employee, consultant, or service provider agreements. Included in operating expenses were $180,562 and $58,250 in stock-based compensation for the three-months ended September 30, 2018 and 2017, respectively.

Other income (expenses), net, were $(1,257) and $(397) for the three-months ended September 30, 2018 and 2017, respectively and primarily consisted of interest income and expense.

Operating Summary for the Nine-Months Ended September 30, 2018 and 2017

We sell ZanthoSyn® primarily through wholesale and e-commerce channels. We launched our e-commerce channel in August 2016 and began selling to GNC stores in Hawaii on January 25, 2017 and GNC corporate stores across the United States on August 10, 2017. As a result, revenues were $1,134,899 and $496,088 for the nine-months ended September 30, 2018 and 2017, respectively. Costs of goods sold were $521,353 and $222,056 for the nine-months ended September 30, 2018 and 2017, respectively, and included costs of the product, shipping and handling, sales taxes, merchant fees, and other costs incurred on the sale of goods. Gross profits were $613,546 and $274,032 for the three-months ended September 30, 2018 and 2017, respectively, which represented gross profit margins of approximately 54% and 55%, respectively.

Operating expenses were $3,689,560 and $1,482,719 for the nine-months ended September 30, 2018 and 2017, respectively. The increase in operating expenses was primarily due to (i) sales and marketing personnel and related activities, (ii) partial restoration of employee salaries, (iii) stock-based compensation for new employees and directors, (iv) initiation of a clinical trial, and (v) pharmaceutical development efforts. Operating expenses primarily consisted of expenses for services provided to the Company, including payroll and consultation, for research and development, administration, and sales and marketing. These expenses were paid in accordance with employee, consultant, or service provider agreements. Included in operating expenses were $443,249 and $142,500 in stock-based compensation for the nine-months ended September 30, 2018 and 2017, respectively.

Other income (expenses), net, were $(859) and $11,652 for the nine-months ended September 30, 2018 and 2017, respectively and primarily consisted of interest income and expense. For the nine-months ended September 30, 2017, other income also consisted of a state refundable tax credit of $12,598.

Liquidity and Capital Resources

Since our inception, we have sustained operating losses and have used cash raised by issuing securities in our operations. During the nine-months ended September 30, 2018 and 2017, we used cash in operating activities in the amount of $2,712,155 and $1,397,432, respectively, and incurred net losses of $3,076,873 and $1,197,035, respectively.

We require additional financing in order to continue to fund our operations and pay existing and future liabilities and other obligations. We raised an additional $1.44 million in gross proceeds through the exchange of 9.6 million warrants via a warrant exchange offering that closed on July 27, 2018. On October 5, 2018, we received the subscriptions receivable amount outstanding of $653,278, less $113,616 in placement fees and expenses, to net $539,662.

We intend to raise additional capital that would fund our operations through at least September 30, 2019. We may continue to obtain additional financing from investors through the private placement of our Common Stock and warrants to purchase our Common Stock. Any financing transaction could also, or in the alternative, include the issuance of our debt or convertible debt securities. There can be no assurance that a financing transaction would be available to us on terms and conditions that we determined are acceptable. We also may access capital under the previously reported equity purchase agreement, pursuant to which we have the right, but not the obligation, to sell shares of our Common Stock, as described in our Registration Statement on Form S-1 (333-214049) filed on February 8, 2017.

We cannot give any assurance that we will in the future be able to achieve a level of profitability from the sale of existing or future products or otherwise to sustain our operations. These conditions raise substantial doubt about our ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Any inability to obtain additional financing on acceptable terms will materially and adversely affect us, including requiring us to significantly further curtail or cease business operations altogether.

Our working capital and capital requirements at any given time depend upon numerous factors, including, but not limited to:

	●	revenues from the sale of any products or licenses;
	●	costs of production, marketing and sales capabilities, or other operating expenses; and
	●	costs of research, development, and commercialization of our technologies.

The following is a summary of our cash flows provided by (used in) operating, investing, and provided by financing activities during the periods indicated:

Cash Flow Summary	Nine-months ended September 30, 2018			Nine-months ended September 30, 2017
Net Cash Used in Operating Activities	$	(2,712,155	)	$	(1,397,432	)
Net Cash Used in Investing Activities		(30,483	)		(16,137	)
Net Cash Provided by Financing Activities		704,375			4,053,456
Net Cash (Decrease) Increase for Period		(2,038,263	)		2,639,887
Cash at Beginning of Period		2,236,837			158,433
Cash at End of Period	$	198,574		$	2,798,320

Cash Flows from Operating Activities

During the nine-months ended September 30, 2018 and 2017, our operating activities primarily consisted of receipts and receivables from sales and payments or accruals for employees, directors, and consultants for services related to administration, sales and marketing, research and development, and inventory deposits.

Cash Flows from Investing Activities

During the nine-months ended September 30, 2018 and 2017, our investing activities were related to expenditures on patents.

Cash Flows from Financing Activities

During the nine-months ended September 30, 2018 and 2017, our financing activities consisted of transactions in which we raised proceeds through the issuance of our Common Stock. In June 2018, we commenced an offering to exchange outstanding warrants for shares of our Common Stock under a Form S-4 Registration Statement. The shares of our Common Stock would be issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of our Common Stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants for $1,440,043 in gross proceeds and 9,600,286 shares of our Common Stock. Of this amount, $653,278 was held in escrow as subscriptions receivable as of September 30, 2018. The subscriptions receivable amount was received on October 5, 2018, less $113,616 in placement fees and expenses, to net $539,662.

Our existing liquidity is not sufficient to fund our operations, anticipated capital expenditures, working capital, and other financing requirements for the foreseeable future. We will need to seek to obtain additional equity or debt financing, especially if we experience downturns or cyclical fluctuations in our business that are more severe or longer than anticipated, or if we experience significant increases in the cost of components and manufacturing or increases in our expense levels resulting from being a publicly-traded company. If we attempt to obtain additional equity or debt financing, we cannot assure you that such financing will be available to us on favorable terms, or at all.

Off-Balance Sheet Arrangements

There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide the information called for by this Item.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that (a) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (b) provide reasonable assurance that transactions are recorded as necessary to permit the preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are being made only in accordance with authorizations of the our management and directors; and (c) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements. Based on our evaluation under the framework in Internal Control—Integrated Framework, our management concluded that our internal control over financial reporting was effective as of September 30, 2018.

Changes in Internal Controls over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2018 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide the information called for by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

There were no unregistered sales of equity securities issued during the three-months ended September 30, 2018.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits.

Exhibit No.		Description
31.1⁽¹⁾		Certification of the Chief Executive Officer pursuant to Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2⁽¹⁾		Certification of the Chief Financial Officer pursuant to Exchange Act Rule 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1⁽¹⁾		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2⁽¹⁾		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS⁽²⁾		XBRL Instance Document

101.SCH⁽²⁾		XBRL Taxonomy Extension Schema Document

101.CAL⁽²⁾		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF⁽²⁾		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB⁽²⁾		XBRL Taxonomy Extension Label Linkbase Document

101.PRE⁽²⁾		XBRL Taxonomy Extension Presentation Linkbase Document

⁽¹⁾		Filed herewith.
⁽²⁾		Furnished herewith. Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of any registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise are not subject to liability under those sections.

SIGNATURES

Pursuant to the requirements of Section 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 13, 2018

	CARDAX, INC.

	By:	/s/ David G. Watumull
	Name:	David G. Watumull
	Title:	Chief Executive Officer and President

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David G. Watumull, Chief Executive Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Cardax, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 13, 2018	/s/ David G. Watumull
	David G. Watumull
	Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, John B. Russell, Chief Financial Officer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Cardax, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: November 13, 2018	/s/ John B. Russell
	John B. Russell
	Chief Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Cardax, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, David G. Watumull, Chief Executive Officer, do hereby certify, to my knowledge:

(1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: November 13, 2018

By:	/s/ David G. Watumull
	David G. Watumull
	Chief Executive Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Cardax, Inc. and will be retained by Cardax, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Cardax, Inc. (the “Company”) on Form 10-Q for the quarterly period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, John B. Russell, Chief Financial Officer, do hereby certify, to my knowledge:

(1) The Quarterly Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: November 13, 2018

By:	/s/ John B. Russell
	John B. Russell
	Chief Financial Officer

EX-101.INS 6 cdxi-20180930.xml XBRL INSTANCE FILE 0001544238 2018-01-01 2018-09-30 0001544238 2017-12-31 0001544238 2008-12-31 0001544238 2009-12-31 0001544238 us-gaap:TechnologyEquipmentMember 2017-12-31 0001544238 srt:MinimumMember 2017-01-01 2017-12-31 0001544238 srt:MaximumMember 2017-01-01 2017-12-31 0001544238 CDXI:CommonStockWarrantsMember 2018-01-01 2018-09-30 0001544238 CDXI:CommonStockWarrantsMember 2017-01-01 2017-09-30 0001544238 2014-02-06 2014-02-07 0001544238 2014-01-02 2014-01-03 0001544238 2014-01-03 0001544238 2014-02-07 0001544238 2013-05-31 0001544238 CDXI:TwoThousandFourteenEquityCompensationPlanMember 2014-02-06 2014-02-07 0001544238 2013-12-31 0001544238 2013-01-01 2013-12-31 0001544238 2015-11-24 0001544238 2016-12-31 0001544238 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001544238 CDXI:SelfDirectedStockIssuanceMember 2017-01-01 2017-12-31 0001544238 CDXI:RestrictedStockOneMember 2017-01-01 2017-12-31 0001544238 CDXI:RestrictedStockTwoMember 2017-01-01 2017-12-31 0001544238 CDXI:RestrictedStockThreeMember 2017-01-01 2017-12-31 0001544238 2015-11-23 2015-11-24 0001544238 CDXI:TwoThousandAndFourteenEquityCompensationPlanAndTwoThousandSixStockIncentivePlanMember 2018-01-01 2018-09-30 0001544238 us-gaap:WarrantMember 2016-12-31 0001544238 CDXI:TwoThousandAndFourteenEquityCompensationPlanAndTwoThousandSixStockIncentivePlanMember srt:MaximumMember 2018-01-01 2018-09-30 0001544238 CDXI:TwoThousandFourteenEquityCompensationPlanMember 2015-04-16 0001544238 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001544238 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001544238 CDXI:RestrictedStockFourMember 2017-01-01 2017-12-31 0001544238 us-gaap:WarrantMember 2017-12-31 0001544238 CDXI:WarrantExerciseMember 2017-01-01 2017-12-31 0001544238 CDXI:WarrantExerciseMember 2017-12-31 0001544238 CDXI:WarrantExerciseOneMember 2017-01-01 2017-12-31 0001544238 CDXI:WarrantExerciseOneMember 2017-12-31 0001544238 CDXI:SelfDirectedStockIssuanceOneMember 2017-01-01 2017-12-31 0001544238 CDXI:SelfDirectedStockIssuanceOneMember 2017-12-31 0001544238 CDXI:SelfDirectedStockIssuanceTwoMember 2017-01-01 2017-12-31 0001544238 CDXI:SelfDirectedStockIssuanceTwoMember 2017-12-31 0001544238 CDXI:RestrictedStockFiveMember 2017-01-01 2017-12-31 0001544238 CDXI:EquityPurchaseAgreementMember us-gaap:InvestorMember 2016-07-01 2016-07-31 0001544238 CDXI:RestrictedCommonStockMember 2017-05-01 2017-05-31 0001544238 CDXI:RestrictedCommonStockMember 2017-05-31 0001544238 CDXI:RestrictedCommonStockOneMember 2017-05-01 2017-05-31 0001544238 CDXI:RestrictedCommonStockTwoMember 2017-05-01 2017-05-31 0001544238 CDXI:RestrictedCommonStockThreeMember 2017-05-01 2017-05-31 0001544238 CDXI:ConsultantMember 2017-04-09 2017-04-10 0001544238 CDXI:ConsultantMember 2017-08-07 2017-08-08 0001544238 CDXI:StockOptionExerciseMember 2017-01-01 2017-12-31 0001544238 CDXI:StockOptionExerciseMember 2017-12-31 0001544238 CDXI:StockOptionExerciseOneMember 2017-01-01 2017-12-31 0001544238 CDXI:StockOptionExerciseOneMember 2017-12-31 0001544238 CDXI:StockOptionExerciseTwoMember 2017-01-01 2017-12-31 0001544238 CDXI:StockOptionExerciseTwoMember 2017-12-31 0001544238 2018-03-21 2018-03-22 0001544238 2018-09-30 0001544238 2017-01-01 2017-09-30 0001544238 2017-09-30 0001544238 CDXI:UnitedStatesMember 2018-01-01 2018-09-30 0001544238 CDXI:UnitedStatesMember 2017-01-01 2017-09-30 0001544238 us-gaap:TechnologyEquipmentMember 2018-09-30 0001544238 CDXI:EuropeCanadaAndBrazilMember 2018-01-01 2018-09-30 0001544238 us-gaap:DirectorMember 2018-01-01 2018-09-30 0001544238 2017-01-01 2017-12-31 0001544238 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001544238 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001544238 us-gaap:WarrantMember 2018-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:ManoaInnovationCenterMember 2018-01-01 2018-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:ManoaInnovationCenterMember 2017-01-01 2017-09-30 0001544238 2018-01-01 2018-01-31 0001544238 2018-06-30 0001544238 CDXI:SelfDirectedStockIssuanceThreeMember 2017-01-01 2017-12-31 0001544238 CDXI:SelfDirectedStockIssuanceThreeMember 2017-12-31 0001544238 CDXI:RestrictedStockSixMember 2017-01-01 2017-12-31 0001544238 CDXI:EquityPurchaseAgreementMember 2018-01-01 2018-09-30 0001544238 CDXI:EquityPurchaseAgreementMember 2017-01-01 2017-09-30 0001544238 CDXI:EffectiveJanuaryEighteenMember 2018-03-21 2018-03-22 0001544238 CDXI:HongKongMember 2018-01-01 2018-09-30 0001544238 CDXI:HongKongMember 2017-01-01 2017-09-30 0001544238 CDXI:ConsultantMember CDXI:AprilTenTwoThousandSeventeenMember 2018-01-01 2018-09-30 0001544238 srt:MinimumMember 2018-01-01 2018-09-30 0001544238 srt:MaximumMember 2018-01-01 2018-09-30 0001544238 2018-07-01 2018-09-30 0001544238 2017-07-01 2017-09-30 0001544238 2018-11-13 0001544238 us-gaap:WarrantMember 2018-05-01 2018-05-02 0001544238 us-gaap:WarrantMember 2018-06-30 0001544238 CDXI:StockOptionExerciseMember 2018-01-01 2018-09-30 0001544238 CDXI:StockOptionExerciseMember 2018-09-30 0001544238 CDXI:StockOptionExerciseOneMember 2018-01-01 2018-09-30 0001544238 CDXI:StockOptionExerciseTwoMember 2018-01-01 2018-09-30 0001544238 us-gaap:DirectorMember 2017-01-01 2017-09-30 0001544238 CDXI:ConsultantMember CDXI:AprilTenTwoThousandSeventeenMember 2017-01-01 2017-09-30 0001544238 CDXI:ConsultantMember 2017-08-30 2017-09-01 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:ManoaInnovationCenterMember 2018-07-01 2018-09-30 0001544238 CDXI:LeaseSettlementAgreementMember CDXI:ManoaInnovationCenterMember 2017-07-01 2017-09-30 0001544238 us-gaap:WarrantMember 2018-07-26 2018-07-27 0001544238 CDXI:ConsultantMember 2018-01-01 2018-09-30 0001544238 2018-07-26 2018-07-27 0001544238 2016-08-09 0001544238 CDXI:ConsultantMember 2017-01-01 2017-09-30 0001544238 CDXI:InvestmentBankersMember 2018-01-01 2018-09-30 0001544238 us-gaap:SubsequentEventMember 2018-10-04 2018-10-05 0001544238 CDXI:OctoberFiveTwoThousandEighteenMember 2018-01-01 2018-09-30 0001544238 CDXI:EuropeCanadaChinaIndiaJapanAndHongKongMember 2018-01-01 2018-09-30 0001544238 CDXI:RestrictedStockOneMember 2017-12-31 0001544238 CDXI:RestrictedStockTwoMember 2017-12-31 0001544238 CDXI:RestrictedStockThreeMember 2017-12-31 0001544238 CDXI:RestrictedStockFourMember 2017-12-31 0001544238 CDXI:RestrictedStockFiveMember 2017-12-31 0001544238 CDXI:RestrictedStockSixMember 2017-12-31 0001544238 CDXI:RestrictedCommonStockOneMember 2017-05-31 0001544238 CDXI:RestrictedCommonStockTwoMember 2017-05-31 0001544238 CDXI:RestrictedCommonStockThreeMember 2017-05-31 0001544238 CDXI:InvestmentBankersMember 2018-09-30 0001544238 us-gaap:SubsequentEventMember 2018-10-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure CDXI:Units CDXI:PatentApplications CARDAX, INC. 10-Q 2018-09-30 false --12-31

0.001

0.21

400000000

122674516

133338573

A summary of stock option activity is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted average exercise price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted average remaining contractual term in years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Aggregate intrinsic value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%">Outstanding January 1, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">36,821,969</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">0.41</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">5.94</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">301,273</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable January 1, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">36,771,969</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5.94</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">299,273</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,161,458</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(770,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">38,213,427</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5.23</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">562,456</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">36,213,427</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.98</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">562,456</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(350,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,833,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(156,997</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(43,003</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">39,496,761</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.64</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">986,808</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">36,580,097</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.28</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">963,475</td> <td style="line-height: 107%"> </td></tr> </table>

Non-accelerated Filer CDXI

NOTE 12 – BASIC AND DILUTED NET LOSS PER SHARE   The following table sets forth the computation of the Company’s basic and diluted net loss per share for:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three-months ended September 30, 2018 (Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Net Loss  (Numerator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares  (Denominator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per share  amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; line-height: 107%">Basic loss per share</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(928,888</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">130,083,598</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">(0.01</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Effect of dilutive securities—Common stock options and warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diluted loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(928,888</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">130,083,598</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.01</td> <td style="line-height: 107%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three-months ended September 30, 2017(Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Net Loss  (Numerator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares  (Denominator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per share  amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Basic loss per share</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(363,156</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">100,587,843</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">(0.00</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Effect of dilutive securities—Common stock options and warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diluted loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(363,156</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">100,587,843</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.00</td> <td style="line-height: 107%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine-months ended September 30, 2018 (Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Net Loss  (Numerator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares  (Denominator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per share  amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Basic loss per share</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(3,076,873</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">125,271,516</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">(0.02</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Effect of dilutive securities—Common stock options and warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diluted loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(3,076,873</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">125,271,516</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.02</td> <td style="line-height: 107%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine-months ended September 30, 2017 (Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Net Loss  (Numerator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares  (Denominator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per share  amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Basic loss per share</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(1,197,035</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">92,513,317</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">(0.01</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Effect of dilutive securities—Common stock options and warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diluted loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(1,197,035</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">92,513,317</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.01</td> <td style="line-height: 107%">)</td></tr> </table>   The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September  30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September  30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Common stock options</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">39,496,761</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 19%; text-align: right; line-height: 107%">36,838,427</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Common stock warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">118,148,846</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">127,018,546</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total common stock equivalents</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">157,645,607</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">163,856,973</td> <td style="line-height: 107%"> </td></tr> </table>

A summary of the Company’s non-vested options for the year ended December 31, 2017, and nine-months ended September 30, 2018, are presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 107%">Non-vested at January 1, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 24%; text-align: right; line-height: 107%">50,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,161,458</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Vested</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(211,458</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-vested at December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,000,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,833,334</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Vested</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(566,670</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(350,000</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-vested at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,916,664</td> <td style="line-height: 107%"> </td></tr> </table>

The range of fair value assumptions related to options issued were as follows for the:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine-months ended September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Year ended December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 107%">Dividend yield</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 21%; text-align: right; line-height: 107%">0.0</td> <td style="width: 1%; line-height: 107%">%</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 21%; text-align: right; line-height: 107%">0.0</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Risk-free rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.38% - 2.80</td> <td style="line-height: 107%">%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.89% - 2.26</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">217% - 226</td> <td style="line-height: 107%">%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">221% - 232</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected term</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3 - 7 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5 - 7 years</td> <td style="line-height: 107%"> </td></tr> </table>

443249

142500

5750

11500

4375

8750

0001544238

50000000

1901

0.001

443249

142500

180562

58250

704375

179000

3774456

44700

4013456

124979

3156685

1555232

426610

435141

2728174

1120091

22838

24052

90831

119066

340425

326174

37243

452225

125271516

92513317

130083598

100587843

125271516

92513317

130083598

100587843

-0.02

-0.01

-0.00

-0.02

-0.01

-0.00

-3076873

-1197035

-928888

-363156

-859

11652

-1257

-397

3356

2790

1264

1073

1941

1844

676

-3076014

-1208687

-927631

-362759

3689560

1482719

1237019

535413

23853

22189

6718

7388

214093

74215

86115

1798

613546

274032

309388

172654

556

12598

-30483

-16137

-2712155

-1397432

50752

55979

55230

-25720

1214

229

118168

74850

-14251

43963

193168

276303

0.625

0.10

0.08

0.625

0.07

0.155

0.06

156997

770000

The Company recognized stock-based compensation expense related to options during the:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine-months ended September 30</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; text-align: justify; line-height: 107%">Employee compensation</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">450,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">156,875</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Compensation for outside services</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">375,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">76,250</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">50,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3,500</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Director compensation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">161,458</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">25,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">825,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">233,125</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">211,458</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">28,500</td> <td style="line-height: 107%"> </td></tr> </table>

233217

500000

1500000

645288

156997

9600286

825000

30420148

211458

15000000

1.00

0.10 1.10 1.00 100000 45000 625000 100000 50000 50000 124712 43003

38213427

36821969

39496761

36213427

36771969

36580097

1833334

2161458

43003

0.41

P4Y11M23D

P10Y

P5Y11M8D

562456

301273

986808

562456

299273

963475

2000000

50000

2916664

566670

211458

0.000

0.0189

0.0226

0.0238

0.0280

2.21

2.32

2.17

2.26

P5Y

P7Y

P3Y

P7Y

375000 50000 76250 3500 161458

25000

233125

28500

3321600

6276960

14446777

392047

2237500

31453788

416595

558750

64783

40000

88365036

127434122

118148846

88365036 127434122 118148846

40259133

315010

-798000

9600286

392047

0.30 0.24 0.20 0.30 0.24 0.20 P3Y6M P3Y1M24D P3Y6M P3Y1M24D P3Y1M24D P2Y6M25D P3Y1M24D P2Y6M25D

543770

3957689

7848637

543770 3957689 7848637

0.21

0.35

0.21

-3076873

-1197035

-928888

-363156

-3076873

-1197035

-928888

-363156

157645607

118148846

127018546

39496761

36838427

163856973

14953

29662

23935

5602

8760

8164

89933

450000 156875

1619

2018

NOTE 1 – COMPANY BACKGROUND   Cardax Pharmaceuticals, Inc. (“Holdings”) was incorporated in the State of Delaware on March 23, 2006.   Holdings was formed for the purpose of developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play important causative roles. Holdings’ platform has application in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. Holdings’ current primary focus is on the development of astaxanthin technologies. Astaxanthin is a naturally occurring marine compound that has robust anti-oxidant and anti-inflammatory activity.   In May of 2013, Holdings formed a 100% owned subsidiary company called Cardax Pharma, Inc. (“Pharma”). Pharma was formed to maintain Holdings’ operations going forward, leaving Holdings as an investment holding company.   On November 29, 2013, Holdings entered into a definitive merger agreement (“Merger Agreement”) with Koffee Korner Inc., a Delaware corporation (“Koffee Korner”) (OTCQB:KOFF), and its wholly owned subsidiary (“Koffee Sub”), pursuant to which, among other matters and subject to the conditions set forth in such Merger Agreement, Koffee Sub would merge with and into Pharma. In connection with such merger agreement and related agreements, upon the consummation of such merger, Pharma would become a wholly owned subsidiary of Koffee Korner and Koffee Korner would issue shares of its common stock to Holdings. At the effective time of such merger, Holdings would own a majority of the shares of the then issued and outstanding shares of common stock of Koffee Korner.   On February 7, 2014, Holdings completed its merger with Koffee Korner, which was renamed to Cardax, Inc. (the “Company”) (OTCQB:CDXI). Concurrent with the merger: (i) the Company received aggregate gross cash proceeds of $3,923,100 in exchange for the issuance and sale of an aggregate 6,276,960 of shares of the Company’s common stock, together with five year warrants to purchase an aggregate of 6,276,960 shares of the Company’s common stock at $0.625 per share, (ii) the notes issued on January 3, 2014, in the outstanding principal amount of $2,076,000 and all accrued interest thereon, automatically converted into 3,353,437 shares of the Company’s common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 3,321,600 shares of common stock at $0.625 per share, (iii) the notes issued in 2013, in the outstanding principal amount of $8,489,036 and all accrued interest thereon, automatically converted into 14,446,777 shares of the Company’s common stock upon the reverse merger at $0.625 per share, together with five year warrants to purchase 14,446,777 shares of common stock at $0.625 per share, (iv) stock options to purchase 15,290,486 shares of Holdings common stock at $0.07 per share were cancelled and substituted with stock options to purchase 6,889,555 shares of the Company’s common stock at $0.155 per share, (v) additional stock options to purchase 20,867,266 shares of the Company’s common stock at $0.625 per share were issued, and (vi) the notes issued in 2008 and 2009, in the outstanding principal amounts of $55,000 and $500,000, respectively, and all accrued interest thereon, were repaid in full. The assets and liabilities of Koffee Korner were distributed in accordance with the terms of a spin-off agreement on the closing date.    The share exchange transaction was treated as a reverse acquisition, with Holdings and Pharma as the acquirers and Koffee Korner and Koffee Sub as the acquired parties. Unless the context suggests otherwise, when the Company refers to business and financial information for periods prior to the consummation of the reverse acquisition, the Company is referring to the business and financial information of Holdings and Pharma. Under accounting principles generally accepted in the United States of America (“U.S. GAAP”) guidance Accounting Standards Codification (“ASC”) No. 805-40, Business Combinations – Reverse Acquisitions, the Acquisition has been treated as a reverse acquisition with no adjustment to the historical book and tax basis of the Company’s assets and liabilities.   On August 28, 2014, the Company entered into an Agreement and Plan of Merger (the “Holdings Merger Agreement”) with its principal stockholder, Holdings, pursuant to which Holdings would merge with and into the Company (the “Holdings Merger”). On September 18, 2015, the Company filed a Form S-4 with the SEC in contemplation of the Holdings Merger. There would not be any cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the stockholders of Holdings would receive an aggregate number of shares and warrants to purchase shares of the Company’s common stock equal to the aggregate number of shares of the Company’s common stock that were held by Holdings on the date of the closing of the Holdings Merger. The Company’s restricted shares of common stock held by Holdings would be cancelled upon the closing of the Holdings Merger. Accordingly, there would not be not any change to the Company’s fully diluted capitalization due to the Holdings Merger.   On November 24, 2015, the Holdings Merger Agreement was amended and restated (the “Amended Holdings Merger Agreement”). Under the terms of Amended Holdings Merger Agreement, the shares of common stock, par value $0.001 per share of Holdings and the shares of all other issued and outstanding capital stock of Holdings that by their terms were convertible or could otherwise be exchanged for shares of Holdings common stock, would be converted into and exchanged for the Company’s shares of Common Stock in a ratio of approximately 2.2:1. In addition, the Company would grant Holdings’ option and warrant holders warrants to purchase the Company’s warrants at the same stock conversion ratio. On November 24, 2015, the Company filed an amendment to the Form S-4 with the SEC and on March 29, 2015, the Form S-4 was declared effective by the SEC.   On December 30, 2015, the Company completed its merger with Holdings, pursuant to the Amended Holdings Merger Agreement. At closing, Holdings merged with and into the Company, with the Company surviving the Holdings Merger. Pursuant to the Amended Holdings Merger Agreement, there was not any cash consideration exchanged in the Holdings Merger. Upon the closing of the Holdings Merger, the stockholders of Holdings received an aggregate number of shares and warrants to purchase shares of Company common stock equal to the aggregate number of shares of Company common stock that were held by Holdings on the date of the closing of the Holdings Merger. The Company’s restricted shares of common stock held by Holdings were cancelled upon the closing of the Holdings Merger. Accordingly, there was not any change to the Company’s fully diluted capitalization due to the Holdings Merger.   The Company is engaged in the development and commercialization of dietary supplements and pharmaceuticals. The Company’s first commercial product, ZanthoSyn®, is a physician recommended anti-inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The Company sells ZanthoSyn® primarily through wholesale and e-commerce channels. The Company is also developing astaxanthin and related compounds, including CDX-085, for pharmaceutical applications. The safety and efficacy of the Company’s products have not been directly evaluated in clinical trials or confirmed by the FDA.   Going concern matters   The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred net losses of $928,888 and $3,076,873, for the three and nine-months ended September 30, 2018, respectively, and net losses of $363,156 and $1,197,035 for the three and nine-months ended September 30, 2017, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $60,995,969 as of September 30, 2018, and has had negative cash flows from operating activities since inception. The Company expects that its marketing program for ZanthoSyn® will continue to focus on outreach to physicians, healthcare professionals, retail personnel, and consumers, and anticipates further losses in the development of its business. As a result of these and other factors, management has determined there is substantial doubt about the Company’s ability to continue as a going concern.   During the quarter ended September 30, 2018, the Company raised additional capital to carry out its business plan. As part of the Company’s efforts, it raised an additional $1.44 million in gross proceeds through the exchange of 9.6 million warrants via a warrant exchange offering that closed on July 27, 2018. As of September 30, 2018, $653,278 of this amount remained in an escrow account as subscriptions receivable and was collected on October 5, 2018, less $113,616 in placement fees and expenses, to net $539,662.   The Company’s continued ability to raise additional capital through future equity and debt securities issuances is unknown. Obtaining additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The condensed consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Unaudited interim financial information   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2018 and 2017.   Unaudited interim financial information (continued)   Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC.   These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on March 27, 2018.   Revenue from contracts with customers   In May 2014, the Financial Accounting Standards Board (“FASB”) issued a new standard related to revenue recognition. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.   The Company adopted this standard effective January 1, 2018, using the retrospective method. As there was no impact on contracts that were previously completed and no significant impact to contracts completed after adoption, there was no need to restate prior results from operations.   The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration.   The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: justify; line-height: 107%">Geographical area</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Source</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; text-align: justify; line-height: 107%">United States</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 12%; text-align: right; line-height: 107%">Nutraceuticals</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">1,118,486</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">496,088</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Hong Kong</td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">Nutraceuticals</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">16,413</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale.   Other significant accounting policies   There have been no other material changes to our significant accounting policies during the nine-months ended September 30, 2018, as compared to the significant accounting policies described in our Annual Report.   Recently issued accounting pronouncements not yet adopted   In February 2016, the FASB issued ASU No. 2016-02, Leases. This ASU requires management to recognize lease assets and lease liabilities for all leases. ASU No. 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous lease guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The guidance in ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently assessing the impact of this ASU on the Company’s condensed consolidated financial statements.   In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent accounting for employee share-based compensation. The guidance in ASU No. 2018-07 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018. The Company is currently in the process of evaluating the impact of the adoption of this ASU on its condensed consolidated financial statements.   In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the FASB’s Concepts Statement, including the consideration of costs and benefits. The guidance in ASU No. 2018-13 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019. The Company is currently in the process of evaluating the impact of the adoption of this ASU on its condensed consolidated financial statements.   Recently adopted accounting pronouncements   In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 23). The amendments of ASU No. 2017-18 require that a statement of cash flow explain the change during a period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The guidance of ASU No. 2016-18 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company has assessed the impact of this ASU and does not believe that this update has a significant impact on its condensed consolidated financial statements.   In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation: Scope of Modification Accounting. The amendments of ASU No. 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance of ASU No. 2017-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company has assessed the impact of this ASU and does not believe that this update has a significant impact on its condensed consolidated financial statements.   The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the condensed consolidated financial statements.   Reclassifications   The Company has made certain reclassifications to conform its prior periods’ data to the current presentation, such as reclassifying a separation agreement that has terms extending beyond one year. These reclassifications had no effect on the reported results of operations or cash flows.

NOTE 3 – INVENTORIES   Inventories consist of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2018  (Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Finished goods</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">267,543</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">240,917</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Raw materials</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">58,631</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">98,937</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Packing supplies and materials</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">571</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total inventories</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">326,174</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">340,425</td> <td style="line-height: 107%"> </td></tr> </table>

NOTE 4 – PROPERTY AND EQUIPMENT, net   Property and equipment, net, consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> September 30, 2018 (Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Information technology equipment</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">31,892</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less accumulated depreciation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(29,991</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total property and equipment, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,901</td> <td style="line-height: 107%"> </td></tr> </table>   Depreciation expense was $0 and $1,901, for the three and nine-months ended September 30, 2018, respectively, and $1,496 and $4,513, for the three and nine-months ended September 30, 2017, respectively.   During the nine-months ended September 30, 2018, Company wrote off its fully depreciated equipment. There was no gain or loss recognized for this write-off.

NOTE 5 – INTANGIBLE ASSETS, net   Intangible assets, net, consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> September 30, 2018 (Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Patents</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">522,575</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">493,027</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less accumulated amortization</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(285,795</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(263,843</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">236,780</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">229,184</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Patents pending</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">198,361</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">197,426</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total intangible assets, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">435,141</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">426,610</td> <td style="line-height: 107%"> </td></tr> </table>   Patents are amortized straight-line over a period of fifteen years. Amortization expense was $6,717 and $21,952 for the three and nine-months ended September 30, 2018, respectively, and $5,892 and $17,676 for the three and nine-months ended September 30, 2017, respectively.   The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved.   The Company owns 25 issued patents, including 14 in the United States and 11 others in Europe, Canada, China, India, Japan, and Hong Kong. These patents will expire beginning in 2023 through 2028, subject to any patent term extensions of the individual patent. The Company has 3 foreign patent applications pending in Europe and Brazil.

NOTE 7 – STOCKHOLDERS’ DEFICIT   Warrant exchange   In June 2018, the Company commenced an offering to exchange outstanding warrants for shares of common stock under a Form S-4 Registration Statement. These shares of common stock would be issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of common stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants for $1,440,043 in gross proceeds and 9,600,286 shares of common stock. Of this amount, $653,278 was held in escrow as subscriptions receivable as of September 30, 2018 and received on October 5, 2018, less $113,616 in placement fees and expenses, to net $539,662.   Self-directed stock issuance   During the year ended December 31, 2017, the Company sold securities in a self-directed offering in the aggregate amount of $179,000, $3,774,456, and $124,979 at $0.08, $0.12, and $0.30, respectively, per unit. Each $0.08 unit consisted of 1 share of restricted common stock (2,237,500 shares), a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.08 per share, a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.12 per share, and a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.16 per share. Each $0.12 unit consisted of 1 share of restricted common stock (31,453,788 shares) and a five-year warrant to purchase 1 share of restricted common stock (31,453,788 warrant shares) at $0.12 per share. Each $0.30 unit consisted of 1 share of restricted common stock (416,595 shares) and a five-year warrant to purchase 1 share of restricted common stock (416,595 warrant shares) at $0.30 per share.   Equity purchase agreement   In July 2016, the Company entered into an equity purchase agreement (the “EPA”) and a registration rights agreement with an investor. Pursuant to the terms of the EPA, the Company has the right, but not the obligation, to sell shares of its common stock to the investor on the terms specified in the EPA. On the date of the EPA, the Company issued 1,500,000 shares to the investor. The total fair value of this stock on the date of grant was $106,500. These shares were fully vested upon issuance.   During the nine-months ended September 30, 2018 and 2017, the Company sold 0 and 567,644 shares of common stock for $0 and $60,000, respectively, pursuant to the EPA.   Payable settlement   In May 2017, the Company settled a payable in the amount of $44,700 with a previously engaged broker dealer through the issuance of securities at $0.08 per unit. Each unit consisted of 1 share of restricted common stock (558,750 shares), a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.08 per share, a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.16 per share.   Shares outstanding   As of September 30, 2018 and December 31, 2017, the Company had a total of 133,338,573 and 122,674,516, respectively, shares of common stock outstanding.

NOTE 8 – STOCK GRANTS   Director stock grants   During the nine-months ended September 30, 2018 and 2017, the Company granted its independent directors an aggregate of 906,774 and 418,025 shares of restricted common stock in the Company, respectively. These shares were fully vested upon issuance. The increase in number of shares issued was due to the expansion of the Board of Directors by two members in June 2018. The total fair value of this stock on the date of grant was $200,000 and $93,750 for the nine-months ended September 30, 2018 and 2017, respectively.   Consultant stock grants   On April 10, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.23 per share. These shares were subject to a risk of forfeiture and vested quarterly in arrears commencing on April 1, 2017. The Company recognized $5,750 and $11,500 in stock based compensation related to this grant during the nine-months ended September 30, 2018 and 2017, respectively.   On August 8, 2017, the Company granted a consultant 100,000 shares of restricted common stock valued at $0.175 per share. These shares were subject to a risk of forfeiture and vested 25% upon grant and quarterly in arrears thereafter commencing on September 1, 2017. The Company recognized $4,375 and $8,750 in stock based compensation related to this grant during the nine-months ended September 30, 2018 and 2017, respectively.

NOTE 9 – STOCK OPTION PLANS   On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares that could be issued under this plan upon adoption was 30,420,148. On April 16, 2015, the majority stockholder of the Company approved an increase in the Company’s 2014 Equity Compensation Plan by 15 million shares.   Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years.   A summary of stock option activity is as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Options</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted average exercise price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted average remaining contractual term in years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Aggregate intrinsic value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%">Outstanding January 1, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">36,821,969</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">0.41</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">5.94</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">301,273</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable January 1, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">36,771,969</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5.94</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">299,273</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,161,458</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(770,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">38,213,427</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5.23</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">562,456</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">36,213,427</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.98</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">562,456</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(350,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,833,334</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(156,997</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(43,003</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">39,496,761</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.64</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">986,808</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">36,580,097</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.41</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">4.28</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">963,475</td> <td style="line-height: 107%"> </td></tr> </table>   The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on September 30, 2018, based on a valuation of the Company’s stock for that day.   A summary of the Company’s non-vested options for the year ended December 31, 2017, and nine-months ended September 30, 2018, are presented below:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 72%; line-height: 107%">Non-vested at January 1, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 24%; text-align: right; line-height: 107%">50,000</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,161,458</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Vested</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(211,458</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-vested at December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2,000,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1,833,334</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Vested</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(566,670</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(350,000</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Non-vested at September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">2,916,664</td> <td style="line-height: 107%"> </td></tr> </table>   The Company estimates the fair value of stock options granted on each grant date using the Black-Scholes option valuation model and recognizes an expense ratably over the requisite service period. The range of fair value assumptions related to options issued were as follows for the:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine-months ended September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Year ended December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%; line-height: 107%">Dividend yield</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 21%; text-align: right; line-height: 107%">0.0</td> <td style="width: 1%; line-height: 107%">%</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 21%; text-align: right; line-height: 107%">0.0</td> <td style="width: 1%; line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Risk-free rate</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.38% - 2.80</td> <td style="line-height: 107%">%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">1.89% - 2.26</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Expected volatility</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">217% - 226</td> <td style="line-height: 107%">%</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">221% - 232</td> <td style="line-height: 107%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Expected term</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3 - 7 years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5 - 7 years</td> <td style="line-height: 107%"> </td></tr> </table>   The expected volatility was calculated based on the historical volatility of the Company. The risk-free interest rate used was based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected dividend yield was zero, because the Company does not anticipate paying a dividend within the relevant timeframe. Due to a lack of historical information needed to estimate the Company’s expected term, it was estimated using the simplified method allowed.   The Company records forfeitures as they occur and reverses compensation cost previously recognized, in the period the award is forfeited, for an award that is forfeited before completion of the requisite service period.   Stock option exercise   During the nine-months ended September 30, 2018, the Company issued 156,997 shares of common stock in connection with the cashless exercise of stock options for 100,000, 50,000, and 50,000 shares of common stock exercisable at $0.06 per share with 43,003 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.   During the year ended December 31, 2017, the Company issued 645,288 shares of common stock in connection with the cashless exercise of stock options for 100,000, 45,000, and 625,000 shares of common stock exercisable at $0.155, $0.06, and $0.06, respectively, per share with 124,712 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.   Stock based compensation   The Company recognized stock-based compensation expense related to options during the:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine-months ended September 30</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Number</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; text-align: justify; line-height: 107%">Employee compensation</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">450,000</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">156,875</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Compensation for outside services</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">375,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">76,250</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">50,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3,500</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Director compensation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">161,458</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">25,000</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify; line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">825,000</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">233,125</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">211,458</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">28,500</td> <td style="line-height: 107%"> </td></tr> </table>

NOTE 10 – WARRANTS   The following is a summary of the Company’s warrant activity:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted average exercise price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted average remaining contractual term in years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Aggregate intrinsic value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%">Outstanding January 1, 2017</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">88,365,036</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">0.30</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 11%; text-align: right; line-height: 107%">3.50</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">543,770</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable January 1, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">88,365,036</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.30</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.50</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">543,770</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">40,259,133</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(798,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(392,047</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">127,434,122</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.24</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.15</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3,957,689</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">127,434,122</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.24</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.15</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3,957,689</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">315,010</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9,600,286</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">118,148,846</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.20</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.57</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">7,848,637</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">118,148,846</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.20</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.57</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">7,848,637</td> <td style="line-height: 107%"> </td></tr> </table>   The Company estimates the fair value of warrants granted on each grant date using the Black-Scholes option valuation model. The expected volatility is calculated based on the historical volatility of the Company. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the warrants to be valued. The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. Due to a lack of historical information needed to estimate the Company’s expected term, it is estimated using the simplified method allowed.   The Company did not recognize any stock-based compensation expense related to warrants during the nine-months ended September 30, 2018 and 2017, respectively.   Warrant exercise   During the year ended December 31, 2017, the Company issued 233,217 shares of common stock in connection with the cashless exercise of a warrant for 298,000 shares of common stock at $0.10 per share with 64,783 shares of common stock withheld with an aggregate fair market value equal to the aggregate exercise price.   During the year ended December 31, 2017, the Company issued 500,000 shares of common stock in connection with the exercise of a warrant for 500,000 shares of common stock at $0.08 per share in exchange for $40,000.   Warrant expiration   During the year ended December 31, 2017, warrants to purchase an aggregate of 392,047 shares of restricted common stock expired.   Warrant exchange   In June 2018, the Company commenced an offering to exchange outstanding warrants for shares of common stock under a Form S-4 Registration Statement. These shares of common stock would be issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of common stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants for $1,440,043 in gross proceeds and 9,600,286 shares of common stock. Of this amount, $653,278 was held in escrow as subscriptions receivable as of September 30, 2018. The subscriptions receivable amount was received on October 5, 2018, less $113,616 in placement fees and expenses, to net $539,662. As part of this exchange, warrants to purchase 315,010 shares of common stock at $0.21 per share were issued to investment bankers for their services.

NOTE 11 – INCOME TAXES   The Company accounts for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon the difference between the financial statement carrying amounts and the tax basis of assets and liabilities and are measured using the enacted tax rate expected to apply to taxable income in the years in which the differences are expected to be reversed.   The effective tax rate for the three and nine-months ended September 30, 2018 and 2017, differs from the statutory rate of 21% as a result of state taxes (net of Federal benefit), permanent differences, and a reserve against deferred tax assets.   The Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes, which requires an assessment of both negative and positive evidence when measuring the need for a valuation allowance. Based on the available objective evidence and the Company’s history of losses, management provides no assurance that the net deferred tax assets will be realized. As of September 30, 2018 and December 31, 2017, the Company has applied a valuation allowance against its deferred tax assets net of the expected income from the reversal of the deferred tax liabilities.   Recent tax legislation   On March 22, 2018, the Tax Cuts and Jobs Act (“TCJA”) was enacted into law, which significantly changes existing U.S. tax law and includes numerous provisions that affect our business, such as reducing the U.S. federal statutory tax rate from 35% to 21% effective January 1, 2018.   Uncertain tax positions   The Company is subject to taxation in the United States and two state jurisdictions. The preparation of tax returns requires management to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. Management, in consultation with its tax advisors, files its tax returns based on interpretations that are believed to be reasonable under the circumstances. The income tax returns, however, are subject to routine reviews by the various taxing authorities. As part of these reviews, a taxing authority may disagree with respect to the tax positions taken by management (“uncertain tax positions”) and therefore may require the Company to pay additional taxes.   Management evaluates the requirement for additional tax accruals, including interest and penalties, which the Company could incur as a result of the ultimate resolution of its uncertain tax positions. Management reviews and updates the accrual for uncertain tax positions as more definitive information becomes available from taxing authorities, completion of tax audits, expiration of statute of limitations, or upon occurrence of other events.   As of September 30, 2018 and December 31, 2017, there was no liability for income tax associated with unrecognized tax benefits. The Company recognizes accrued interest related to unrecognized tax benefits as well as any related penalties in interest income or expense in its condensed consolidated statements of operations, which is consistent with the recognition of these items in prior reporting periods.   The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed.

NOTE 13 – LEASES   Manoa Innovation Center   The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $8,760 and $29,662, for the three and nine-months ended September 30, 2018, respectively, and $8,164 and $23,935, for the three and nine-months ended September 30, 2017, respectively.   Fleet Lease   In January 2018, the Company entered into a vehicle lease arrangement with a rental company for three vehicles. The terms of the leases require total monthly payments of $1,619 for three years. These leases convert to month-to-month leases in January 2021 unless terminated. Total rent expense under this agreement was $5,602 and $14,953, for the three and nine-months ended September 30, 2018, respectively, and $0 for the three and nine-months ended September 30, 2017.

NOTE 14 – SUBSEQUENT EVENTS   The Company evaluated all material events through the date the financials were ready for issuance. On October 5, 2018, the Company received the subscriptions receivable amount outstanding of $653,278, less $113,616 in placement fees and expenses, to net $539,662.

The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: justify; line-height: 107%">Geographical area</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Source</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; text-align: justify; line-height: 107%">United States</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 12%; text-align: right; line-height: 107%">Nutraceuticals</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">1,118,486</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">496,088</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Hong Kong</td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">Nutraceuticals</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">16,413</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>

Inventories consist of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September 30, 2018  (Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Finished goods</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">267,543</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">240,917</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Raw materials</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">58,631</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">98,937</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Packing supplies and materials</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">571</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total inventories</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">326,174</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">340,425</td> <td style="line-height: 107%"> </td></tr> </table>

Property and equipment, net, consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> September 30, 2018 (Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Information technology equipment</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">-</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">31,892</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less accumulated depreciation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(29,991</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total property and equipment, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">1,901</td> <td style="line-height: 107%"> </td></tr> </table>

Intangible assets, net, consists of the following as of:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> September 30, 2018 (Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">December 31, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Patents</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">522,575</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 19%; text-align: right; line-height: 107%">493,027</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less accumulated amortization</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(285,795</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(263,843</td> <td style="line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">236,780</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">229,184</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Patents pending</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">198,361</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">197,426</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total intangible assets, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">435,141</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">426,610</td> <td style="line-height: 107%"> </td></tr> </table>

The following is a summary of the Company’s warrant activity:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Warrants</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted average exercise price</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Weighted average remaining contractual term in years</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Aggregate intrinsic value</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%; line-height: 107%">Outstanding January 1, 2017</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">88,365,036</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 11%; text-align: right; line-height: 107%">0.30</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 10%; text-align: right; line-height: 107%">3.50</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 10%; text-align: right; line-height: 107%">543,770</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable January 1, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">88,365,036</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.30</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.50</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">543,770</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">40,259,133</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">(798,000</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">(392,047</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">127,434,122</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.24</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.15</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3,957,689</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable December 31, 2017</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">127,434,122</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.24</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">3.15</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">3,957,689</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Canceled</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Granted</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">315,010</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%">Exercised</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">9,600,286</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%">Forfeited</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Outstanding September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">118,148,846</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.20</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.57</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">7,848,637</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Exercisable September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">118,148,846</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">0.20</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">2.57</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">7,848,637</td> <td style="line-height: 107%"> </td></tr> </table>

The following table sets forth the computation of the Company’s basic and diluted net loss per share for:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three-months ended September 30, 2018 (Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Net Loss  (Numerator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares  (Denominator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per share  amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%; line-height: 107%">Basic loss per share</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(928,888</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">130,083,598</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">(0.01</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Effect of dilutive securities—Common stock options and warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diluted loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(928,888</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">130,083,598</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.01</td> <td style="line-height: 107%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Three-months ended September 30, 2017(Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Net Loss  (Numerator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares  (Denominator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per share  amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Basic loss per share</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(363,156</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">100,587,843</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">(0.00</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Effect of dilutive securities—Common stock options and warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diluted loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(363,156</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">100,587,843</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.00</td> <td style="line-height: 107%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine-months ended September 30, 2018 (Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Net Loss  (Numerator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares  (Denominator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per share  amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Basic loss per share</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(3,076,873</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">125,271,516</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">(0.02</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Effect of dilutive securities—Common stock options and warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diluted loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(3,076,873</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">125,271,516</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.02</td> <td style="line-height: 107%">)</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Nine-months ended September 30, 2017 (Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Net Loss  (Numerator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Shares  (Denominator)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Per share  amount</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; line-height: 107%">Basic loss per share</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">(1,197,035</td> <td style="width: 1%; line-height: 107%">)</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 13%; text-align: right; line-height: 107%">92,513,317</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 13%; text-align: right; line-height: 107%">(0.01</td> <td style="width: 1%; line-height: 107%">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Effect of dilutive securities—Common stock options and warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Diluted loss per share</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(1,197,035</td> <td style="line-height: 107%">)</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">92,513,317</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">(0.01</td> <td style="line-height: 107%">)</td></tr> </table>

The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the periods ended:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September  30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">September  30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 54%; line-height: 107%">Common stock options</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 20%; text-align: right; line-height: 107%">39,496,761</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 19%; text-align: right; line-height: 107%">36,838,427</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Common stock warrants</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">118,148,846</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">127,018,546</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Total common stock equivalents</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">157,645,607</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">163,856,973</td> <td style="line-height: 107%"> </td></tr> </table>

0.15

3404610

3450570

603391

875957

418546

50000

4562162

4795073

4647777

4889958

122675

133339

56401069

58067566

10125

-57919096

-60995969

-1405477

-3334726

3156685

1555232

704375

4053456

-2038263

2639887

2236837

158433

198574

2798320

3356

2790

P4Y

521353

222056

240152

149207

350000

133338573

1168747

492895

350630

213538

637042

299569

225875

124769

539662

1202576

451351

387119

129670

44700

221814 Unaudited interim financial information   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2018 and 2017.   Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC.   These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the related notes included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC on March 27, 2018.

Revenue from contracts with customers   In May 2014, the Financial Accounting Standards Board (“FASB”) issued a new standard related to revenue recognition. Under the standard, revenue is recognized when a customer obtains control of promised goods or services in an amount that reflects the consideration the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers.   The Company adopted this standard effective January 1, 2018, using the retrospective method. As there was no impact on contracts that were previously completed and no significant impact to contracts completed after adoption, there was no need to restate prior results from operations.   The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration.   The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30, 2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="text-align: center; line-height: 107%">September 30, 2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: justify; line-height: 107%">Geographical area</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">Source</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">(Unaudited)</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%; text-align: justify; line-height: 107%">United States</td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 12%; text-align: right; line-height: 107%">Nutraceuticals</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 2%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 15%; text-align: right; line-height: 107%">1,118,486</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">496,088</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify; line-height: 107%">Hong Kong</td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">Nutraceuticals</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">16,413</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%">$</td> <td style="text-align: right; line-height: 107%">-</td> <td style="line-height: 107%"> </td></tr> </table>   Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale.

Other significant accounting policies   There have been no other material changes to our significant accounting policies during the nine-months ended September 30, 2018, as compared to the significant accounting policies described in our Annual Report. Recently issued accounting pronouncements not yet adopted   In February 2016, the FASB issued ASU No. 2016-02, Leases. This ASU requires management to recognize lease assets and lease liabilities for all leases. ASU No. 2016-02 retains a distinction between finance leases and operating leases. The classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the previous lease guidance. The result of retaining a distinction between finance leases and operating leases is that under the lessee accounting model, the effect of leases in the statement of comprehensive income and the statement of cash flows is largely unchanged from previous U.S. GAAP. The guidance in ASU No. 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently assessing the impact of this ASU on the Company’s condensed consolidated financial statements.   In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. This ASU is intended to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent accounting for employee share-based compensation. The guidance in ASU No. 2018-07 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2018. The Company is currently in the process of evaluating the impact of the adoption of this ASU on its condensed consolidated financial statements.   In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the FASB’s Concepts Statement, including the consideration of costs and benefits. The guidance in ASU No. 2018-13 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019. The Company is currently in the process of evaluating the impact of the adoption of this ASU on its condensed consolidated financial statements.

Recently adopted accounting pronouncements   In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 23). The amendments of ASU No. 2017-18 require that a statement of cash flow explain the change during a period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The guidance of ASU No. 2016-18 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company has assessed the impact of this ASU and does not believe that this update has a significant impact on its condensed consolidated financial statements.   In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation: Scope of Modification Accounting. The amendments of ASU No. 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance of ASU No. 2017-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. The Company has assessed the impact of this ASU and does not believe that this update has a significant impact on its condensed consolidated financial statements.   The Company does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the condensed consolidated financial statements.

Reclassifications   The Company has made certain reclassifications to conform its prior periods’ data to the current presentation, such as reclassifying a separation agreement that has terms extending beyond one year. These reclassifications had no effect on the reported results of operations or cash flows.

1.00

3923100

60000

6276960

567644

P5Y P5Y P5Y

2076000

8489036

3353437

14446777

0.625

15290486 6889555 0.155 20867266 0.625

55000

500000

Common Stock in a ratio of approximately 2.2:1

98937

58631

240917

267543

571

1901

4513

1496

31892

29991

P15Y

21952

17676

6717

5892

25 14 11 3

493027

522575

229184

236780

197426 198361

426610

435141

2237500

558750

100000

906774

418025

200000

93750

0.23 0.175

0.25

-3076873

-1197035

-928888

-363156

1440043

1440000

1134899

496088

1118486

496088

16413

549540

321861

Patents will expire beginning in 2023 through 2028

0.08

0.12

0.08

0.30

Each $0.08 unit consisted of 1 share of restricted common stock (2,237,500 shares), a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.08 per share, a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.12 per share, and a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.16 per share. Each $0.12 unit consisted of 1 share of restricted common stock (31,453,788 shares) and a five-year warrant to purchase 1 share of restricted common stock (31,453,788 warrant shares) at $0.12 per share. Each $0.30 unit consisted of 1 share of restricted common stock (416,595 shares) and a five-year warrant to purchase 1 share of restricted common stock (416,595 warrant shares) at $0.30 per share.

Each unit consisted of 1 share of restricted common stock (558,750 shares), a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.08 per share, a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.16 per share.

0.08 0.12 0.16 0.12 0.30 0.08 0.12 0.16 0.30

106500

122674516

133338573

P5Y2M23D

P5Y11M8D

P4Y7M21D P5Y2M23D P4Y3M11D P4Y11M23D

true true false 85615 94885

539662

40000

539662

NOTE 6 –ACCRUED SEPARATION COSTS   On August 9, 2016, the Company entered into a separation agreement with an employee to pay $118,635 of accrued compensation over nine-years. This amount is included in accrued payroll and payroll related expenses in the accompanying balance sheets. This amount does not yield interest and matures as follows for the twelve-months ended September 30:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">2019</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">9,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2020</td> <td> </td> <td> </td> <td style="text-align: right">9,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">11,250</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2022</td> <td> </td> <td> </td> <td style="text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2023</td> <td> </td> <td> </td> <td style="text-align: right">16,500</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">46,135</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">103,885</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Less current portion</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,000</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">94,885</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

This amount does not yield interest and matures as follows for the twelve-months ended September 30:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 79%">2019</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 18%; text-align: right">9,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2020</td> <td> </td> <td> </td> <td style="text-align: right">9,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">11,250</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2022</td> <td> </td> <td> </td> <td style="text-align: right">12,000</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>2023</td> <td> </td> <td> </td> <td style="text-align: right">16,500</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">46,135</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">103,885</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Less current portion</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(9,000</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">94,885</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

118635

9000 9000 11250 12000 16500 46135 103885 94885 -9000

0.15

315010

653278

298000 500000 9600000

P5Y

30483

16137

263843

285795

113616 113616

EX-101.SCH 7 cdxi-20180930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Company Background link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Accrued Separation Costs link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stock Grants link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stock Option Plans link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Basic and Diluted Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Property and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Accrued Separation Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stock Option Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Basic and Diluted Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Company Background (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue Source and Geographical Location for Sales and Usage-Based Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Property and Equipment, Net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Intangible Assets, Net (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Accrued Separation Costs (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Accrued Separation Costs - Schedule of Accrued Payroll and Payroll Related Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Stockholders' Deficit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Stock Grants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Stock Option Plans (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Stock Option Plans - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Stock Option Plans - Schedule of Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Stock Option Plans - Schedule of Recognized Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Warrants - Schedule of Stock Warrants Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Basic and Diluted Net Loss Per Share - Schedule of Computation of Diluted Net Income (Loss) Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 cdxi-20180930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 cdxi-20180930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 cdxi-20180930_lab.xml XBRL LABEL FILE Property, Plant and Equipment, Type [Axis] Information Technology Equipment [Member] Range [Axis] Minimum [Member] Maximum [Member] Equity Components [Axis] Common Stock Warrants [Member] Plan Name [Axis] 2014 Equity Compensation Plan [Member] Warrant [Member] Self Directed Stock Issuance [Member] Award Type [Axis] Restricted Stock One [Member] Restricted Stock Two [Member] Restricted Stock Three [Member] 2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] Antidilutive Securities [Axis] Common Stock Options [Member] Restricted Stock Four [Member] Warrant Exercise [Member] Warrant Exercise One [Member] Self Directed Stock Issuance one [Member] Self Directed Stock Issuance Two [Member] Restricted Stock Five [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Equity Purchase Agreement [Member] Related Party [Axis] Investor [Member] Restricted Common Stock [Member] Restricted Common Stock One [Member] Restricted Common Stock Two [Member] Restricted Common Stock Three [Member] Consultant [Member] Option Indexed to Issuer's Equity, Type [Axis] Stock Option Exercise [Member] Stock Option Exercise One [Member] Stock Option Exercise Two [Member] Geographical [Axis] United States [Member] Europe, Canada, and Brazil [Member] Director [Member] Lease Arrangement, Type [Axis] Lease Settlement Agreement [Member] Manoa Innovation Center [Member] Self Directed Stock Issuance Three [Member] Restricted Stock Six [Member] Income Tax Authority [Axis] Effective January 1, 2018 [Member] Hong Kong [Member] Scenario [Axis] April 10, 2017 [Member] Investment Bankers [Member] Subsequent Event Type [Axis] Subsequent Event [Member] October 5, 2018 [Member] Europe, Canada, China, India, Japan, and Hong Kong [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash Accounts receivable Inventories Deposits and other assets Prepaid expenses Total current assets PROPERTY AND EQUIPMENT, net INTANGIBLE ASSETS, net TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Accrued payroll and payroll related expenses, current portion Accounts payable and accrued expenses Fees payable to directors Employee settlement Total current liabilities ACCRUED PAYROLL AND PAYROLL RELATED EXPENSES, net of current portion COMMITMENTS AND CONTINGENCIES Total liabilities STOCKHOLDERS' DEFICIT Preferred Stock - $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2018, and December 31, 2017, respectively Common stock - $0.001 par value; 400,000,000 shares authorized, 133,338,573 and 122,674,516 shares issued and outstanding as of September 30, 2018, and December 31, 2017, respectively Additional paid-in-capital Subscriptions receivable Deferred compensation Accumulated deficit Total stockholders' deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] REVENUES, net COST OF GOODS SOLD GROSS PROFIT OPERATING EXPENSES: Salaries and wages Selling, general, and administrative expenses Professional fees Stock based compensation Research and development Depreciation and amortization Total operating expenses Loss from operations OTHER INCOME (EXPENSES): Other income Interest income Interest expense Total other (expenses) income, net Loss before the provision for income taxes PROVISION FOR INCOME TAXES NET LOSS NET LOSS PER SHARE Basic Diluted SHARES USED IN CALCULATION OF NET LOSS PER SHARE Basic Diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Stock based compensation Bad debt expense on note receivable and accrued interest Changes in assets and liabilities: Accounts receivable Inventories Deposits and other assets Prepaid expenses Accrued payroll and payroll related expenses Accounts payable and accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Increase in intangible assets Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from the issuance of common stock Proceeds from the exercise of warrants Net cash provided by financing activities NET DECREASE (INCREASE) IN CASH CASH AT THE BEGINNING OF THE PERIOD CASH AT THE END OF THE PERIOD SUPPLEMENTAL DISCLOSURES: Cash paid for interest Cash paid for income taxes NON-CASH INVESTING AND FINANCING ACTIVITIES: Conversion of accounts payable into restricted stock Settlement of receivables with payables Subscription receivable recognized for common shares issued Accounting Policies [Abstract] Company Background Summary of Significant Accounting Policies Inventory Disclosure [Abstract] Inventories Property, Plant and Equipment [Abstract] Property and Equipment, Net Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets, Net Payables and Accruals [Abstract] Accrued Separation Costs Equity [Abstract] Stockholders' Deficit Stock Grants Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock Option Plans Warrants and Rights Note Disclosure [Abstract] Warrants Income Tax Disclosure [Abstract] Income Taxes Earnings Per Share [Abstract] Basic and Diluted Net Loss Per Share Leases [Abstract] Leases EX-101.PRE 11 cdxi-20180930_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Nov. 13, 2018
Document And Entity Information
Entity Registrant Name	CARDAX, INC.
Entity Central Index Key	0001544238
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		133,338,573
Trading Symbol	CDXI
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash	$ 198,574	$ 2,236,837
Accounts receivable	452,225	37,243
Inventories	326,174	340,425
Deposits and other assets	119,066	90,831
Prepaid expenses	24,052	22,838
Total current assets	1,120,091	2,728,174
PROPERTY AND EQUIPMENT, net		1,901
INTANGIBLE ASSETS, net	435,141	426,610
TOTAL ASSETS	1,555,232	3,156,685
CURRENT LIABILITIES
Accrued payroll and payroll related expenses, current portion	3,450,570	3,404,610
Accounts payable and accrued expenses	875,957	603,391
Fees payable to directors	418,546	418,546
Employee settlement	50,000	50,000
Total current liabilities	4,795,073	4,562,162
ACCRUED PAYROLL AND PAYROLL RELATED EXPENSES, net of current portion	94,885	85,615
COMMITMENTS AND CONTINGENCIES
Total liabilities	4,889,958	4,647,777
STOCKHOLDERS' DEFICIT
Preferred Stock - $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding as of September 30, 2018, and December 31, 2017, respectively
Common stock - $0.001 par value; 400,000,000 shares authorized, 133,338,573 and 122,674,516 shares issued and outstanding as of September 30, 2018, and December 31, 2017, respectively	133,339	122,675
Additional paid-in-capital	58,067,566	56,401,069
Subscriptions receivable	(539,662)
Deferred compensation		(10,125)
Accumulated deficit	(60,995,969)	(57,919,096)
Total stockholders' deficit	(3,334,726)	(1,405,477)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,555,232	$ 3,156,685

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	133,338,573	122,674,516
Common stock, shares outstanding	133,338,573	122,674,516

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
REVENUES, net	$ 549,540	$ 321,861	$ 1,134,899	$ 496,088
COST OF GOODS SOLD	240,152	149,207	521,353	222,056
GROSS PROFIT	309,388	172,654	613,546	274,032
OPERATING EXPENSES:
Salaries and wages	387,119	129,670	1,202,576	451,351
Selling, general, and administrative expenses	350,630	213,538	1,168,747	492,895
Professional fees	225,875	124,769	637,042	299,569
Stock based compensation	180,562	58,250	443,249	142,500
Research and development	86,115	1,798	214,093	74,215
Depreciation and amortization	6,718	7,388	23,853	22,189
Total operating expenses	1,237,019	535,413	3,689,560	1,482,719
Loss from operations	(927,631)	(362,759)	(3,076,014)	(1,208,687)
OTHER INCOME (EXPENSES):
Other income			556	12,598
Interest income	7	676	1,941	1,844
Interest expense	(1,264)	(1,073)	(3,356)	(2,790)
Total other (expenses) income, net	(1,257)	(397)	(859)	11,652
Loss before the provision for income taxes	(928,888)	(363,156)	(3,076,873)	(1,197,035)
PROVISION FOR INCOME TAXES
NET LOSS	$ (928,888)	$ (363,156)	$ (3,076,873)	$ (1,197,035)
NET LOSS PER SHARE
Basic	$ (0.01)	$ (0.00)	$ (0.02)	$ (0.01)
Diluted	$ (0.01)	$ (0.00)	$ (0.02)	$ (0.01)
SHARES USED IN CALCULATION OF NET LOSS PER SHARE
Basic	130,083,598	100,587,843	125,271,516	92,513,317
Diluted	130,083,598	100,587,843	125,271,516	92,513,317

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,076,873)	$ (1,197,035)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	23,853	22,189
Stock based compensation	443,249	142,500
Bad debt expense on note receivable and accrued interest	89,933
Changes in assets and liabilities:
Accounts receivable	(193,168)	(276,303)
Inventories	14,251	(43,963)
Deposits and other assets	(118,168)	(74,850)
Prepaid expenses	(1,214)	(229)
Accrued payroll and payroll related expenses	55,230	(25,720)
Accounts payable and accrued expenses	50,752	55,979
Net cash used in operating activities	(2,712,155)	(1,397,432)
CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in intangible assets	(30,483)	(16,137)
Net cash used in investing activities	(30,483)	(16,137)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of common stock	704,375	4,013,456
Proceeds from the exercise of warrants		40,000
Net cash provided by financing activities	704,375	4,053,456
NET DECREASE (INCREASE) IN CASH	(2,038,263)	2,639,887
CASH AT THE BEGINNING OF THE PERIOD	2,236,837	158,433
CASH AT THE END OF THE PERIOD	198,574	2,798,320
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	3,356	2,790
Cash paid for income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of accounts payable into restricted stock		44,700
Settlement of receivables with payables	221,814
Subscription receivable recognized for common shares issued	$ 539,662

XML 17 R6.htm IDEA: XBRL DOCUMENT

Company Background

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Company Background

NOTE 1 – COMPANY BACKGROUND

Cardax Pharmaceuticals, Inc. (“Holdings”) was incorporated in the State of Delaware on March 23, 2006.

Going concern matters

XML 18 R7.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Unaudited interim financial information

Unaudited interim financial information (continued)

Revenue from contracts with customers

The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended:

		September 30, 2018		September 30, 2017
Geographical area	Source	(Unaudited)		(Unaudited)
United States	Nutraceuticals	$	1,118,486	$	496,088
Hong Kong	Nutraceuticals	$	16,413	$	-

Other significant accounting policies

Recently issued accounting pronouncements not yet adopted

Recently adopted accounting pronouncements

Reclassifications

XML 19 R8.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Inventories

NOTE 3 – INVENTORIES

Inventories consist of the following as of:

	September 30, 2018 (Unaudited)		December 31, 2017
Finished goods	$	267,543	$	240,917
Raw materials		58,631		98,937
Packing supplies and materials		-		571
Total inventories	$	326,174	$	340,425

XML 20 R9.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net

9 Months Ended

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

NOTE 4 – PROPERTY AND EQUIPMENT, net

Property and equipment, net, consists of the following as of:

	September 30, 2018 (Unaudited)		December 31, 2017
Information technology equipment	$	-	$	31,892
Less accumulated depreciation		-		(29,991	)
Total property and equipment, net	$	-	$	1,901

During the nine-months ended September 30, 2018, Company wrote off its fully depreciated equipment. There was no gain or loss recognized for this write-off.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Intangible Assets, Net

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets, Net

NOTE 5 – INTANGIBLE ASSETS, net

Intangible assets, net, consists of the following as of:

	September 30, 2018 (Unaudited)			December 31, 2017
Patents	$	522,575		$	493,027
Less accumulated amortization		(285,795	)		(263,843	)
		236,780			229,184
Patents pending		198,361			197,426
Total intangible assets, net	$	435,141		$	426,610

XML 22 R11.htm IDEA: XBRL DOCUMENT

Accrued Separation Costs

9 Months Ended

Sep. 30, 2018

Payables and Accruals [Abstract]

Accrued Separation Costs

NOTE 6 –ACCRUED SEPARATION COSTS

2019	$	9,000
2020		9,000
2021		11,250
2022		12,000
2023		16,500
Thereafter		46,135
		103,885
Less current portion		(9,000	)
	$	94,885

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Stockholders' Deficit

NOTE 7 – STOCKHOLDERS’ DEFICIT

Warrant exchange

Self-directed stock issuance

Equity purchase agreement

During the nine-months ended September 30, 2018 and 2017, the Company sold 0 and 567,644 shares of common stock for $0 and $60,000, respectively, pursuant to the EPA.

Payable settlement

Shares outstanding

As of September 30, 2018 and December 31, 2017, the Company had a total of 133,338,573 and 122,674,516, respectively, shares of common stock outstanding.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Stock Grants

9 Months Ended

Sep. 30, 2018

Equity [Abstract]

Stock Grants

NOTE 8 – STOCK GRANTS

Director stock grants

Consultant stock grants

XML 25 R14.htm IDEA: XBRL DOCUMENT

Stock Option Plans

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Option Plans

NOTE 9 – STOCK OPTION PLANS

A summary of stock option activity is as follows:

	Options			Weighted average exercise price		Weighted average remaining contractual term in years		Aggregate intrinsic value
Outstanding January 1, 2017		36,821,969		$	0.41		5.94	$	301,273
Exercisable January 1, 2017		36,771,969		$	0.41		5.94	$	299,273
Canceled		-
Granted		2,161,458
Exercised		(770,000	)		-
Forfeited		-
Outstanding December 31, 2017		38,213,427		$	0.41		5.23	$	562,456
Exercisable December 31, 2017		36,213,427		$	0.41		4.98	$	562,456
Canceled		(350,000	)
Granted		1,833,334
Exercised		(156,997	)		-
Forfeited		(43,003	)
Outstanding September 30, 2018		39,496,761		$	0.41		4.64	$	986,808
Exercisable September 30, 2018		36,580,097		$	0.41		4.28	$	963,475

A summary of the Company’s non-vested options for the year ended December 31, 2017, and nine-months ended September 30, 2018, are presented below:

Non-vested at January 1, 2017	50,000
Granted	2,161,458
Vested	(211,458	)
Canceled	-
Non-vested at December 31, 2017	2,000,000
Granted	1,833,334
Vested	(566,670	)
Canceled	(350,000	)
Non-vested at September 30, 2018	2,916,664

	Nine-months ended September 30, 2018			Year ended December 31, 2017
Dividend yield		0.0	%		0.0	%
Risk-free rate		2.38% - 2.80	%		1.89% - 2.26	%
Expected volatility		217% - 226	%		221% - 232	%
Expected term		3 - 7 years			5 - 7 years

Stock option exercise

Stock based compensation

The Company recognized stock-based compensation expense related to options during the:

	Nine-months ended September 30
	2018				2017
	Number		Amount		Number		Amount

Employee compensation		450,000	$	156,875		-	$	-
Compensation for outside services		375,000		76,250		50,000		3,500
Director compensation		-		-		161,458		25,000

Total		825,000	$	233,125		211,458	$	28,500

XML 26 R15.htm IDEA: XBRL DOCUMENT

Warrants

9 Months Ended

Sep. 30, 2018

Warrants and Rights Note Disclosure [Abstract]

Warrants

NOTE 10 – WARRANTS

The following is a summary of the Company’s warrant activity:

	Warrants			Weighted average exercise price		Weighted average remaining contractual term in years		Aggregate intrinsic value
Outstanding January 1, 2017		88,365,036		$	0.30		3.50	$	543,770
Exercisable January 1, 2017		88,365,036		$	0.30		3.50	$	543,770
Canceled		-
Granted		40,259,133
Exercised		(798,000	)
Forfeited		(392,047	)
Outstanding December 31, 2017		127,434,122		$	0.24		3.15	$	3,957,689
Exercisable December 31, 2017		127,434,122		$	0.24		3.15	$	3,957,689
Canceled		-
Granted		315,010
Exercised		9,600,286
Forfeited		-
Outstanding September 30, 2018		118,148,846		$	0.20		2.57	$	7,848,637
Exercisable September 30, 2018		118,148,846		$	0.20		2.57	$	7,848,637

The Company did not recognize any stock-based compensation expense related to warrants during the nine-months ended September 30, 2018 and 2017, respectively.

Warrant exercise

Warrant expiration

During the year ended December 31, 2017, warrants to purchase an aggregate of 392,047 shares of restricted common stock expired.

Warrant exchange

In June 2018, the Company commenced an offering to exchange outstanding warrants for shares of common stock under a Form S-4 Registration Statement. These shares of common stock would be issued to warrant holders in exchange for (i) their outstanding warrants to purchase shares of common stock at $0.625 per share, and (ii) cash payment of $0.15 per share. This offering closed on July 27, 2018, and resulted in an exchange of 9.6 million warrants for $1,440,043 in gross proceeds and 9,600,286 shares of common stock. Of this amount, $653,278 was held in escrow as subscriptions receivable as of September 30, 2018. The subscriptions receivable amount was received on October 5, 2018, less $113,616 in placement fees and expenses, to net $539,662. As part of this exchange, warrants to purchase 315,010 shares of common stock at $0.21 per share were issued to investment bankers for their services.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Income Taxes

NOTE 11 – INCOME TAXES

Recent tax legislation

Uncertain tax positions

The federal and state income tax returns of the Company are subject to examination by the IRS and state taxing authorities, generally for three years after they were filed.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Share

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Basic and Diluted Net Loss Per Share

NOTE 12 – BASIC AND DILUTED NET LOSS PER SHARE

The following table sets forth the computation of the Company’s basic and diluted net loss per share for:

	Three-months ended September 30, 2018 (Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(928,888	)		130,083,598	$	(0.01	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(928,888	)		130,083,598	$	(0.01	)

	Three-months ended September 30, 2017(Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(363,156	)		100,587,843	$	(0.00	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(363,156	)		100,587,843	$	(0.00	)

	Nine-months ended September 30, 2018 (Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(3,076,873	)		125,271,516	$	(0.02	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(3,076,873	)		125,271,516	$	(0.02	)

	Nine-months ended September 30, 2017 (Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(1,197,035	)		92,513,317	$	(0.01	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(1,197,035	)		92,513,317	$	(0.01	)

	September 30, 2018		September 30, 2017
	(Unaudited)		(Unaudited)
Common stock options		39,496,761		36,838,427
Common stock warrants		118,148,846		127,018,546
Total common stock equivalents		157,645,607		163,856,973

XML 29 R18.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended

Sep. 30, 2018

Leases [Abstract]

Leases

NOTE 13 – LEASES

Manoa Innovation Center

Fleet Lease

XML 30 R19.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2018

Subsequent Events [Abstract]

Subsequent Events

NOTE 14 – SUBSEQUENT EVENTS

XML 31 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Unaudited Interim Financial Information

Unaudited interim financial information

Revenue from Contracts with Customers

Revenue from contracts with customers

The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended:

		September 30, 2018		September 30, 2017
Geographical area	Source	(Unaudited)		(Unaudited)
United States	Nutraceuticals	$	1,118,486	$	496,088
Hong Kong	Nutraceuticals	$	16,413	$	-

Other Significant Accounting Policies

Other significant accounting policies

Recently Issued Accounting Pronouncements Not Yet Adopted

Recently issued accounting pronouncements not yet adopted

Recently Adopted Accounting Pronouncements

Recently adopted accounting pronouncements

Reclassifications

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Schedule of Revenue Source and Geographical Location for Sales and Usage-Based Taxes

The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the nine-months ended:

		September 30, 2018		September 30, 2017
Geographical area	Source	(Unaudited)		(Unaudited)
United States	Nutraceuticals	$	1,118,486	$	496,088
Hong Kong	Nutraceuticals	$	16,413	$	-

XML 33 R22.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following as of:

	September 30, 2018 (Unaudited)		December 31, 2017
Finished goods	$	267,543	$	240,917
Raw materials		58,631		98,937
Packing supplies and materials		-		571
Total inventories	$	326,174	$	340,425

XML 34 R23.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net (Tables)

9 Months Ended

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment, Net

Property and equipment, net, consists of the following as of:

	September 30, 2018 (Unaudited)		December 31, 2017
Information technology equipment	$	-	$	31,892
Less accumulated depreciation		-		(29,991	)
Total property and equipment, net	$	-	$	1,901

XML 35 R24.htm IDEA: XBRL DOCUMENT

Intangible Assets, Net (Tables)

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets, Net

Intangible assets, net, consists of the following as of:

	September 30, 2018 (Unaudited)			December 31, 2017
Patents	$	522,575		$	493,027
Less accumulated amortization		(285,795	)		(263,843	)
		236,780			229,184
Patents pending		198,361			197,426
Total intangible assets, net	$	435,141		$	426,610

XML 36 R25.htm IDEA: XBRL DOCUMENT

Accrued Separation Costs (Tables)

9 Months Ended

Sep. 30, 2018

Payables and Accruals [Abstract]

Schedule of Accrued Payroll and Payroll Related Expenses

This amount does not yield interest and matures as follows for the twelve-months ended September 30:

2019	$	9,000
2020		9,000
2021		11,250
2022		12,000
2023		16,500
Thereafter		46,135
		103,885
Less current portion		(9,000	)
	$	94,885

XML 37 R26.htm IDEA: XBRL DOCUMENT

Stock Option Plans (Tables)

9 Months Ended

Sep. 30, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Option Activity

A summary of stock option activity is as follows:

	Options			Weighted average exercise price		Weighted average remaining contractual term in years		Aggregate intrinsic value
Outstanding January 1, 2017		36,821,969		$	0.41		5.94	$	301,273
Exercisable January 1, 2017		36,771,969		$	0.41		5.94	$	299,273
Canceled		-
Granted		2,161,458
Exercised		(770,000	)		-
Forfeited		-
Outstanding December 31, 2017		38,213,427		$	0.41		5.23	$	562,456
Exercisable December 31, 2017		36,213,427		$	0.41		4.98	$	562,456
Canceled		(350,000	)
Granted		1,833,334
Exercised		(156,997	)		-
Forfeited		(43,003	)
Outstanding September 30, 2018		39,496,761		$	0.41		4.64	$	986,808
Exercisable September 30, 2018		36,580,097		$	0.41		4.28	$	963,475

Schedule of Non-Vested Shares Granted Under Stock Option Plan

A summary of the Company’s non-vested options for the year ended December 31, 2017, and nine-months ended September 30, 2018, are presented below:

Non-vested at January 1, 2017	50,000
Granted	2,161,458
Vested	(211,458	)
Canceled	-
Non-vested at December 31, 2017	2,000,000
Granted	1,833,334
Vested	(566,670	)
Canceled	(350,000	)
Non-vested at September 30, 2018	2,916,664

Schedule of Fair Value Assumptions

The range of fair value assumptions related to options issued were as follows for the:

	Nine-months ended September 30, 2018			Year ended December 31, 2017
Dividend yield		0.0	%		0.0	%
Risk-free rate		2.38% - 2.80	%		1.89% - 2.26	%
Expected volatility		217% - 226	%		221% - 232	%
Expected term		3 - 7 years			5 - 7 years

Schedule of Recognized Stock Based Compensation Expense

The Company recognized stock-based compensation expense related to options during the:

	Nine-months ended September 30
	2018				2017
	Number		Amount		Number		Amount

Employee compensation		450,000	$	156,875		-	$	-
Compensation for outside services		375,000		76,250		50,000		3,500
Director compensation		-		-		161,458		25,000

Total		825,000	$	233,125		211,458	$	28,500

XML 38 R27.htm IDEA: XBRL DOCUMENT

Warrants (Tables)

9 Months Ended

Sep. 30, 2018

Warrants and Rights Note Disclosure [Abstract]

Schedule of Stock Warrants Activity

The following is a summary of the Company’s warrant activity:

	Warrants			Weighted average exercise price		Weighted average remaining contractual term in years		Aggregate intrinsic value
Outstanding January 1, 2017		88,365,036		$	0.30		3.50	$	543,770
Exercisable January 1, 2017		88,365,036		$	0.30		3.50	$	543,770
Canceled		-
Granted		40,259,133
Exercised		(798,000	)
Forfeited		(392,047	)
Outstanding December 31, 2017		127,434,122		$	0.24		3.15	$	3,957,689
Exercisable December 31, 2017		127,434,122		$	0.24		3.15	$	3,957,689
Canceled		-
Granted		315,010
Exercised		9,600,286
Forfeited		-
Outstanding September 30, 2018		118,148,846		$	0.20		2.57	$	7,848,637
Exercisable September 30, 2018		118,148,846		$	0.20		2.57	$	7,848,637

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 39 R28.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2018

Earnings Per Share [Abstract]

Schedule of Basic and Diluted Net Income (Loss)

The following table sets forth the computation of the Company’s basic and diluted net loss per share for:

	Three-months ended September 30, 2018 (Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(928,888	)		130,083,598	$	(0.01	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(928,888	)		130,083,598	$	(0.01	)

	Three-months ended September 30, 2017(Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(363,156	)		100,587,843	$	(0.00	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(363,156	)		100,587,843	$	(0.00	)

	Nine-months ended September 30, 2018 (Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(3,076,873	)		125,271,516	$	(0.02	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(3,076,873	)		125,271,516	$	(0.02	)

	Nine-months ended September 30, 2017 (Unaudited)
	Net Loss (Numerator)			Shares (Denominator)		Per share amount
Basic loss per share	$	(1,197,035	)		92,513,317	$	(0.01	)
Effect of dilutive securities—Common stock options and warrants		-			-		-
Diluted loss per share	$	(1,197,035	)		92,513,317	$	(0.01	)

Schedule of Computation of Diluted Net Income (Loss) Per Share

	September 30, 2018		September 30, 2017
	(Unaudited)		(Unaudited)
Common stock options		39,496,761		36,838,427
Common stock warrants		118,148,846		127,018,546
Total common stock equivalents		157,645,607		163,856,973

XML 40 R29.htm IDEA: XBRL DOCUMENT

Company Background (Details Narrative) - USD ($)					3 Months Ended		9 Months Ended		12 Months Ended
Company Background (Details Narrative) - USD ($)	Jul. 27, 2018	Nov. 24, 2015	Feb. 07, 2014	Jan. 03, 2014	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2013	Jun. 30, 2018	Dec. 31, 2017	May 31, 2013	Dec. 31, 2009	Dec. 31, 2008
Ownership interest												100.00%
Proceeds from sale of common stock			$ 3,923,100
Number of common stock shares sold			6,276,960
Warrants term			5 years	5 years					5 years
Cashless exercise of warrants			6,276,960	3,321,600					14,446,777
Warrant exercise price per share			$ 0.625	$ 0.625					$ 0.625	$ 0.625
Outstanding principal amount of notes payable				$ 2,076,000					$ 8,489,036
Shares of common stock issued upon conversion of notes payable				3,353,437					14,446,777
Warrants converted into common stock upon reverse merger				$ 0.625					$ 0.625
Stock options cancelled			15,290,486
Stock option cancelled price per share			$ 0.07
Stock options issued in substitution of cancelled options			6,889,555
Stock options issued in substitution of cancelled options, price per share			$ 0.155
Additional stock options issued purchase number of common stock			20,867,266
Additional stock options issued purchase number of common stock, price per share			$ 0.625
Outstanding principal notes repaid in full													$ 500,000	$ 55,000
Common stock, par value		$ 0.001			$ 0.001		$ 0.001				$ 0.001
Company's shares of common stock in ratio approximately		Common Stock in a ratio of approximately 2.2:1
Net losses					$ 928,888	$ 363,156	$ 3,076,873	$ 1,197,035
Accumulated deficit					60,995,969		60,995,969				$ 57,919,096
Escrow account					653,278		653,278
Placement fees and expenses					$ 225,875	$ 124,769	637,042	$ 299,569
October 5, 2018 [Member]
Amount reduced in placement fees and expenses							113,616
Placement fees and expenses							539,662
Warrant [Member]
Cashless exercise of warrants											392,047
Warrant exercise price per share										$ 0.625
Proceeds from warrants issuances	$ 1,440,000						$ 1,440,043
Cashless exercise of warrants	9,600,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Revenue Source and Geographical Location for Sales and Usage-Based Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total revenue	$ 549,540	$ 321,861	$ 1,134,899	$ 496,088
United States [Member]
Total revenue			1,118,486	496,088
Hong Kong [Member]
Total revenue			$ 16,413

XML 42 R31.htm IDEA: XBRL DOCUMENT

Inventories - Schedule of Inventories (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Finished goods	$ 267,543	$ 240,917
Raw materials	58,631	98,937
Packing supplies and materials		571
Total inventories	$ 326,174	$ 340,425

XML 43 R32.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0	$ 1,496	$ 1,901	$ 4,513

XML 44 R33.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Total property and equipment, net		$ 1,901
Information Technology Equipment [Member]
Information technology equipment		31,892
Less accumulated depreciation		(29,991)
Total property and equipment, net		$ 1,901

XML 45 R34.htm IDEA: XBRL DOCUMENT

Intangible Assets, Net (Details Narrative)	3 Months Ended		9 Months Ended
Intangible Assets, Net (Details Narrative)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2018 USD ($) Units PatentApplications	Sep. 30, 2017 USD ($)
Patent, amortization period			15 years
Amortization expense \| $	$ 6,717	$ 5,892	$ 21,952	$ 17,676
Patents, units			25
Patents expiration date			Patents will expire beginning in 2023 through 2028
United States [Member]
Patents, units \| Units			14
Europe, Canada, China, India, Japan, and Hong Kong [Member]
Patents, units			11
Europe, Canada, and Brazil [Member]
Number of patent application pending			3

XML 46 R35.htm IDEA: XBRL DOCUMENT

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 522,575	$ 493,027
Less accumulated amortization	(285,795)	(263,843)
Patents, Total	236,780	229,184
Patents pending	198,361	197,426
Total intangible assets, net	$ 435,141	$ 426,610

XML 47 R36.htm IDEA: XBRL DOCUMENT

Accrued Separation Costs (Details Narrative)	Aug. 09, 2016 USD ($)
Payables and Accruals [Abstract]
Accrued compensation expenses	$ 118,635

XML 48 R37.htm IDEA: XBRL DOCUMENT

Accrued Separation Costs - Schedule of Accrued Payroll and Payroll Related Expenses (Details)	9 Months Ended
	Sep. 30, 2018 USD ($)
Payables and Accruals [Abstract]
2019	$ 9,000
2020	9,000
2021	11,250
2022	12,000
2023	16,500
Thereafter	46,135
Accrued Separation Costs, gross	103,885
Less current portion	(9,000)
Accrued Separation Costs, net	$ 94,885

XML 49 R38.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details Narrative) - USD ($)			1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
Stockholders' Deficit (Details Narrative) - USD ($)	Jul. 27, 2018	Feb. 07, 2014	May 31, 2017	Jul. 31, 2016	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jun. 30, 2018	Nov. 24, 2015	Jan. 03, 2014	Dec. 31, 2013
Number of common stock issued	9,600,286
Common stock, par value					$ 0.001		$ 0.001		$ 0.001		$ 0.001
Warrants price per share		$ 0.625								$ 0.625		$ 0.625	$ 0.625
Share price										0.15
Escrow account					$ 653,278		$ 653,278
Placement fees and expenses					$ 225,875	$ 124,769	637,042	$ 299,569
Sold securities in a self-directed offering, aggregate amount							$ 704,375	$ 4,013,456
Warrants to purchase of common stock shares		6,276,960										3,321,600	14,446,777
Number of common stock shares sold		6,276,960
Proceeds from sale of common stock		$ 3,923,100
Common stock, shares outstanding					133,338,573		133,338,573		122,674,516
Equity Purchase Agreement [Member]
Number of common stock shares sold							0	567,644
Proceeds from sale of common stock							$ 0	$ 60,000
Equity Purchase Agreement [Member] \| Investor [Member]
Number of common stock issued				1,500,000
Fair value of stock grant fully vested				$ 106,500
October 5, 2018 [Member]
Amount reduced in placement fees and expenses							113,616
Placement fees and expenses							539,662
Restricted Stock One [Member]
Restricted common stock price per share									$ 0.08
Warrants to purchase of common stock shares									2,237,500
Warrants term									5 years
Restricted Stock Two [Member]
Restricted common stock price per share									$ 0.12
Warrants to purchase of common stock shares									2,237,500
Warrants term									5 years
Restricted Stock Three [Member]
Restricted common stock price per share									$ 0.16
Warrants to purchase of common stock shares									2,237,500
Warrants term									5 years
Restricted Stock Four [Member]
Restricted common stock price per share									$ 0.12
Warrants to purchase of common stock shares									31,453,788
Warrants term									5 years
Restricted Stock Five [Member]
Restricted common stock price per share									$ 0.30
Warrants to purchase of common stock shares									416,595
Warrants term									5 years
Restricted Stock Six [Member]
Restricted common stock price per share									$ 0.30
Warrants to purchase of common stock shares									416,595
Warrants term									5 years
Restricted Common Stock [Member]
Sold securities in a self-directed offering, aggregate amount			$ 44,700
Issuance of stock per share			$ 0.08
Conversion stock, description			Each unit consisted of 1 share of restricted common stock (558,750 shares), a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.08 per share, a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.12 per share, and a five-year warrant to purchase 1 share of restricted common stock (558,750 warrant shares) at $0.16 per share.
Number of restricted common stock			558,750
Restricted Common Stock One [Member]
Restricted common stock price per share			$ 0.08
Warrants to purchase of common stock shares			558,750
Warrants term			5 years
Restricted Common Stock Two [Member]
Restricted common stock price per share			$ 0.12
Warrants to purchase of common stock shares			558,750
Warrants term			5 years
Restricted Common Stock Three [Member]
Restricted common stock price per share			$ 0.16
Warrants to purchase of common stock shares			558,750
Warrants term			5 years
Warrant [Member]
Warrants price per share										$ 0.625
Cashless exercise of warrants	9,600,000
Proceeds from warrants issuances	$ 1,440,000						$ 1,440,043
Warrants to purchase of common stock shares									392,047
Self Directed Stock Issuance one [Member]
Sold securities in a self-directed offering, aggregate amount									$ 179,000
Issuance of stock per share									$ 0.08
Self Directed Stock Issuance Two [Member]
Sold securities in a self-directed offering, aggregate amount									$ 3,774,456
Issuance of stock per share									$ 0.12
Self Directed Stock Issuance Three [Member]
Sold securities in a self-directed offering, aggregate amount									$ 124,979
Issuance of stock per share									$ 0.30
Self Directed Stock Issuance [Member]
Conversion stock, description									Each $0.08 unit consisted of 1 share of restricted common stock (2,237,500 shares), a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.08 per share, a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.12 per share, and a five year warrant to purchase 1 share of restricted common stock (2,237,500 warrant shares) at $0.16 per share. Each $0.12 unit consisted of 1 share of restricted common stock (31,453,788 shares) and a five-year warrant to purchase 1 share of restricted common stock (31,453,788 warrant shares) at $0.12 per share. Each $0.30 unit consisted of 1 share of restricted common stock (416,595 shares) and a five-year warrant to purchase 1 share of restricted common stock (416,595 warrant shares) at $0.30 per share.
Number of restricted common stock									2,237,500

XML 50 R39.htm IDEA: XBRL DOCUMENT

Stock Grants (Details Narrative) - USD ($)				9 Months Ended
Stock Grants (Details Narrative) - USD ($)	Sep. 01, 2017	Aug. 08, 2017	Apr. 10, 2017	Sep. 30, 2018	Sep. 30, 2017
Stock compensation expense				$ 443,249	$ 142,500
Director [Member]
Restricted common stock, shares				906,774	418,025
Restricted common stock, value				$ 200,000	$ 93,750
Consultant [Member]
Restricted common stock, shares		100,000	100,000
Restricted common stock, per share		$ 0.175	$ 0.23
Stock compensation expense				4,375	8,750
Share-based payment forfeiture and vesting rights, percentage	25.00%
Consultant [Member] \| April 10, 2017 [Member]
Stock compensation expense				$ 5,750	$ 11,500

XML 51 R40.htm IDEA: XBRL DOCUMENT

Stock Option Plans (Details Narrative) - USD ($)			9 Months Ended		12 Months Ended
Stock Option Plans (Details Narrative) - USD ($)	Jul. 27, 2018	Feb. 07, 2014	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Apr. 16, 2015
Aggregate number of shares issuable under this plan			825,000	211,458
Options default term			4 years 11 months 23 days		5 years 11 months 8 days
Dividend yield			$ 0
Number of common stock shares issued	9,600,286
Common stock per share		$ 0.07
Stock Option Exercise [Member]
Number of common stock shares issued			156,997		645,288
Cashless exercise of a stock option, shares			100,000		100,000
Common stock per share			$ 0.06		$ 0.155
Number of common stock withheld with aggregate exercise price			43,003		124,712
Stock Option Exercise One [Member]
Cashless exercise of a stock option, shares			50,000		45,000
Common stock per share					$ 0.06
Stock Option Exercise Two [Member]
Cashless exercise of a stock option, shares			50,000		625,000
Common stock per share					$ 0.06
2014 Equity Compensation Plan [Member]
Aggregate number of shares issuable under this plan		30,420,148
Shares authorized						15,000,000
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member]
Percentage of stock option granted to stockholders			10.00%
Options default term			10 years
Generally vest term			4 years
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] \| Maximum [Member]
Percentage granted to employees at a price per share			100.00%
Percentage exercise price per share			110.00%
Percentage restricted stock to related parties price per share			100.00%

XML 52 R41.htm IDEA: XBRL DOCUMENT

Stock Option Plans - Schedule of Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options Outstanding, Beginning balance	38,213,427	36,821,969
Options Exercisable, Beginning balance	36,213,427	36,771,969
Options, Canceled	(350,000)
Options, Granted	1,833,334	2,161,458
Options, Exercised	(156,997)	(770,000)
Options, Forfeited	(43,003)
Options Outstanding, Ending balance	39,496,761	38,213,427
Options Exercisable, Ending balance	36,580,097	36,213,427
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.41	$ 0.41
Weighted Average Exercise Price, Exercisable, Beginning balance	0.41	0.41
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending balance	0.41	0.41
Weighted Average Exercise Price, Exercisable, Ending balance	$ 0.41	$ 0.41
Weighted Average Remaining Contractual Term in Years, Outstanding Beginning	5 years 2 months 23 days	5 years 11 months 8 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Beginning	4 years 11 months 23 days	5 years 11 months 8 days
Weighted Average Remaining Contractual Term in Years, Outstanding Ending	4 years 7 months 21 days	5 years 2 months 23 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Ending	4 years 3 months 11 days	4 years 11 months 23 days
Aggregate Intrinsic Value, Outstanding Beginning balance	$ 562,456	$ 301,273
Aggregate Intrinsic Value, Exercisable Beginning balance	562,456	299,273
Aggregate Intrinsic Value, Outstanding Ending balance	986,808	562,456
Aggregate Intrinsic Value, Exercisable Ending balance	$ 963,475	$ 562,456

XML 53 R42.htm IDEA: XBRL DOCUMENT

Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) - shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Non-vested, Options Outstanding, Beginning balance	2,000,000	50,000
Non-vested, Options Granted	1,833,334	2,161,458
Non-vested, Options Vested	(566,670)	(211,458)
Non-vested, Options Canceled	(350,000)
Non-vested, Options Outstanding, Ending balance	2,916,664	2,000,000

XML 54 R43.htm IDEA: XBRL DOCUMENT

Stock Option Plans - Schedule of Fair Value Assumptions (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Dividend yield	0.00%	0.00%
Minimum [Member]
Risk-free rate	2.38%	1.89%
Expected volatility	217.00%	221.00%
Expected term	3 years	5 years
Maximum [Member]
Risk-free rate	2.80%	2.26%
Expected volatility	226.00%	232.00%
Expected term	7 years	7 years

XML 55 R44.htm IDEA: XBRL DOCUMENT

Stock Option Plans - Schedule of Recognized Stock Based Compensation Expense (Details) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Employee compensation , shares	450,000
Employee compensation	$ 156,875
Compensation for outside services, shares	375,000	50,000
Compensation for outside services	$ 76,250	$ 3,500
Director compensation, shares		161,458
Director compensation		$ 25,000
Stock based compensation expense, shares	825,000	211,458
Stock based compensation expense	$ 233,125	$ 28,500

XML 56 R45.htm IDEA: XBRL DOCUMENT

Warrants (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
Warrants (Details Narrative) - USD ($)	Jul. 27, 2018	May 02, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017	Jun. 30, 2018	Nov. 24, 2015	Feb. 07, 2014	Jan. 03, 2014	Dec. 31, 2013
Dividend yield					$ 0
Stock compensation expense					$ 443,249	$ 142,500
Number of common stock shares issued	9,600,286
Warrant price per share								$ 0.625		$ 0.625	$ 0.625	$ 0.625
Warrants to purchase an aggregate number of shares										6,276,960	3,321,600	14,446,777
Common stock par value			$ 0.001		$ 0.001		$ 0.001		$ 0.001
Escrow account			$ 653,278		$ 653,278
Placement fees and expenses			$ 225,875	$ 124,769	$ 637,042	299,569
Investment Bankers [Member]
Common stock par value			$ 0.21		$ 0.21
Issuance of shares issued for services					315,010
October 5, 2018 [Member]
Amount reduced in placement fees and expenses					$ 113,616
Placement fees and expenses					539,662
Warrant [Member]
Stock compensation expense					0	$ 0
Cashless exercise of warrants	9,600,000
Warrant price per share								$ 0.625
Warrants to purchase an aggregate number of shares							392,047
Cash payments		$ 0.15
Proceeds from warrants issuances	$ 1,440,000				$ 1,440,043
Warrant Exercise [Member]
Number of common stock shares issued							233,217
Cashless exercise of warrants							298,000
Warrant price per share							$ 0.10
Aggregate fair market value of common stock withheld							64,783
Warrant Exercise One [Member]
Number of common stock shares issued							500,000
Cashless exercise of warrants							500,000
Warrant price per share							$ 0.08
Number of common stock value issued							$ 40,000

XML 57 R46.htm IDEA: XBRL DOCUMENT

Warrants - Schedule of Stock Warrants Activity (Details) - Warrant [Member] - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Warrants, Outstanding, Beginning balance	127,434,122	88,365,036
Warrants, Exercisable, Beginning balance	127,434,122	88,365,036
Warrants, Canceled
Warrants, Granted	315,010	40,259,133
Warrants, Exercised	9,600,286	(798,000)
Warrants, Forfeited		(392,047)
Warrants, Outstanding, Ending balance	118,148,846	127,434,122
Warrants, Exercisable, Ending balance	118,148,846	127,434,122
Weighted Average Exercise Price, Outstanding, Beginning	$ 0.24	$ 0.30
Weighted Average Exercise Price, Exercisable, Beginning	0.24	0.30
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding, Ending	0.20	0.24
Weighted Average Exercise Price, Exercisable, Ending	$ 0.20	$ 0.24
Weighted Average Remaining Contractual Term in Years, Beginning Outstanding	3 years 1 month 24 days	3 years 6 months
Weighted Average Remaining Contractual Term in Years, Beginning Exercisable	3 years 1 month 24 days	3 years 6 months
Weighted Average Remaining Contractual Term in Years, Ending Outstanding	2 years 6 months 25 days	3 years 1 month 24 days
Weighted Average Remaining Contractual Term in Years, Ending Exercisable	2 years 6 months 25 days	3 years 1 month 24 days
Aggregate Intrinsic Value, Outstanding, Beginning	$ 3,957,689	$ 543,770
Aggregate Intrinsic Value, Exercisable, Beginning	3,957,689	543,770
Aggregate Intrinsic Value, Outstanding, Ending	7,848,637	3,957,689
Aggregate Intrinsic Value, Exercisable, Ending	$ 7,848,637	$ 3,957,689

XML 58 R47.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative)		3 Months Ended		9 Months Ended
Income Taxes (Details Narrative)	Mar. 22, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Effective tax statutory rate	35.00%	21.00%	21.00%	21.00%	21.00%
Effective January 1, 2018 [Member]
Effective tax statutory rate	21.00%

XML 59 R48.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Income (Loss) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Net loss (numerator) Basic loss per share, basic	$ (928,888)	$ (363,156)	$ (3,076,873)	$ (1,197,035)
Net loss (numerator) Effect of dilutive securities-common stock options and warrants
Net loss (numerator) Diluted loss per share, diluted	$ (928,888)	$ (363,156)	$ (3,076,873)	$ (1,197,035)
Shares (denominator) Basic loss per shares , basic	130,083,598	100,587,843	125,271,516	92,513,317
Shares (denominator) Effect of dilutive securities-common stock options and warrants
Shares (denominator) Diluted loss per shares, diluted	130,083,598	100,587,843	125,271,516	92,513,317
Per share amount Basic loss per share, basic	$ (0.01)	$ (0.00)	$ (0.02)	$ (0.01)
Per share amount Effect of dilutive securities-common stock options and warrants
Per share amount Diluted loss per share, diluted	$ (0.01)	$ (0.00)	$ (0.02)	$ (0.01)

XML 60 R49.htm IDEA: XBRL DOCUMENT

Basic and Diluted Net Loss Per Share - Schedule of Computation of Diluted Net Income (Loss) Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Total common stock equivalents	157,645,607	163,856,973
Common Stock Warrants [Member]
Total common stock equivalents	118,148,846	127,018,546
Common Stock Options [Member]
Total common stock equivalents	39,496,761	36,838,427

XML 61 R50.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
Leases (Details Narrative) - USD ($)	Jan. 31, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Rent expenses		$ 5,602	$ 0	$ 14,953	$ 0
Total monthly payment	$ 1,619
Lease Settlement Agreement [Member] \| Manoa Innovation Center [Member]
Rent expenses		$ 8,760	$ 8,164	$ 29,662	$ 23,935

XML 62 R51.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Oct. 05, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Escrow account		$ 653,278		$ 653,278
Placement fees and expenses		$ 225,875	$ 124,769	$ 637,042	$ 299,569
Subsequent Event [Member]
Escrow account	$ 653,278
Placement fees and expenses	539,662
Amount reduced in placement fees and expenses	$ 113,616

EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 118 252 1 false 42 0 false 6 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cardaxpharma.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://cardaxpharma.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://cardaxpharma.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://cardaxpharma.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://cardaxpharma.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Company Background Sheet http://cardaxpharma.com/role/CompanyBackground Company Background Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://cardaxpharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Inventories Sheet http://cardaxpharma.com/role/Inventories Inventories Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment, Net Sheet http://cardaxpharma.com/role/PropertyAndEquipmentNet Property and Equipment, Net Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets, Net Sheet http://cardaxpharma.com/role/IntangibleAssetsNet Intangible Assets, Net Notes 10 false false R11.htm 00000011 - Disclosure - Accrued Separation Costs Sheet http://cardaxpharma.com/role/AccruedSeparationCosts Accrued Separation Costs Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders' Deficit Sheet http://cardaxpharma.com/role/StockholdersDeficit Stockholders' Deficit Notes 12 false false R13.htm 00000013 - Disclosure - Stock Grants Sheet http://cardaxpharma.com/role/StockGrants Stock Grants Notes 13 false false R14.htm 00000014 - Disclosure - Stock Option Plans Sheet http://cardaxpharma.com/role/StockOptionPlans Stock Option Plans Notes 14 false false R15.htm 00000015 - Disclosure - Warrants Sheet http://cardaxpharma.com/role/Warrants Warrants Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://cardaxpharma.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Basic and Diluted Net Loss Per Share Sheet http://cardaxpharma.com/role/BasicAndDilutedNetLossPerShare Basic and Diluted Net Loss Per Share Notes 17 false false R18.htm 00000018 - Disclosure - Leases Sheet http://cardaxpharma.com/role/Leases Leases Notes 18 false false R19.htm 00000019 - Disclosure - Subsequent Events Sheet http://cardaxpharma.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 00000020 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://cardaxpharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://cardaxpharma.com/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://cardaxpharma.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://cardaxpharma.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - Inventories (Tables) Sheet http://cardaxpharma.com/role/InventoriesTables Inventories (Tables) Tables http://cardaxpharma.com/role/Inventories 22 false false R23.htm 00000023 - Disclosure - Property and Equipment, Net (Tables) Sheet http://cardaxpharma.com/role/PropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://cardaxpharma.com/role/PropertyAndEquipmentNet 23 false false R24.htm 00000024 - Disclosure - Intangible Assets, Net (Tables) Sheet http://cardaxpharma.com/role/IntangibleAssetsNetTables Intangible Assets, Net (Tables) Tables http://cardaxpharma.com/role/IntangibleAssetsNet 24 false false R25.htm 00000025 - Disclosure - Accrued Separation Costs (Tables) Sheet http://cardaxpharma.com/role/AccruedSeparationCostsTables Accrued Separation Costs (Tables) Tables http://cardaxpharma.com/role/AccruedSeparationCosts 25 false false R26.htm 00000026 - Disclosure - Stock Option Plans (Tables) Sheet http://cardaxpharma.com/role/StockOptionPlansTables Stock Option Plans (Tables) Tables http://cardaxpharma.com/role/StockOptionPlans 26 false false R27.htm 00000027 - Disclosure - Warrants (Tables) Sheet http://cardaxpharma.com/role/WarrantsTables Warrants (Tables) Tables http://cardaxpharma.com/role/Warrants 27 false false R28.htm 00000028 - Disclosure - Basic and Diluted Net Loss Per Share (Tables) Sheet http://cardaxpharma.com/role/BasicAndDilutedNetLossPerShareTables Basic and Diluted Net Loss Per Share (Tables) Tables http://cardaxpharma.com/role/BasicAndDilutedNetLossPerShare 28 false false R29.htm 00000029 - Disclosure - Company Background (Details Narrative) Sheet http://cardaxpharma.com/role/CompanyBackgroundDetailsNarrative Company Background (Details Narrative) Details http://cardaxpharma.com/role/CompanyBackground 29 false false R30.htm 00000030 - Disclosure - Summary of Significant Accounting Policies - Schedule of Revenue Source and Geographical Location for Sales and Usage-Based Taxes (Details) Sheet http://cardaxpharma.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfRevenueSourceAndGeographicalLocationForSalesAndUsage-basedTaxesDetails Summary of Significant Accounting Policies - Schedule of Revenue Source and Geographical Location for Sales and Usage-Based Taxes (Details) Details 30 false false R31.htm 00000031 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://cardaxpharma.com/role/Inventories-ScheduleOfInventoriesDetails Inventories - Schedule of Inventories (Details) Details 31 false false R32.htm 00000032 - Disclosure - Property and Equipment, Net (Details Narrative) Sheet http://cardaxpharma.com/role/PropertyAndEquipmentNetDetailsNarrative Property and Equipment, Net (Details Narrative) Details http://cardaxpharma.com/role/PropertyAndEquipmentNetTables 32 false false R33.htm 00000033 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Sheet http://cardaxpharma.com/role/PropertyAndEquipmentNet-ScheduleOfPropertyAndEquipmentNetDetails Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) Details 33 false false R34.htm 00000034 - Disclosure - Intangible Assets, Net (Details Narrative) Sheet http://cardaxpharma.com/role/IntangibleAssetsNetDetailsNarrative Intangible Assets, Net (Details Narrative) Details http://cardaxpharma.com/role/IntangibleAssetsNetTables 34 false false R35.htm 00000035 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) Sheet http://cardaxpharma.com/role/IntangibleAssetsNet-ScheduleOfIntangibleAssetsNetDetails Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) Details 35 false false R36.htm 00000036 - Disclosure - Accrued Separation Costs (Details Narrative) Sheet http://cardaxpharma.com/role/AccruedSeparationCostsDetailsNarrative Accrued Separation Costs (Details Narrative) Details http://cardaxpharma.com/role/AccruedSeparationCostsTables 36 false false R37.htm 00000037 - Disclosure - Accrued Separation Costs - Schedule of Accrued Payroll and Payroll Related Expenses (Details) Sheet http://cardaxpharma.com/role/AccruedSeparationCosts-ScheduleOfAccruedPayrollAndPayrollRelatedExpensesDetails Accrued Separation Costs - Schedule of Accrued Payroll and Payroll Related Expenses (Details) Details 37 false false R38.htm 00000038 - Disclosure - Stockholders' Deficit (Details Narrative) Sheet http://cardaxpharma.com/role/StockholdersDeficitDetailsNarrative Stockholders' Deficit (Details Narrative) Details http://cardaxpharma.com/role/StockholdersDeficit 38 false false R39.htm 00000039 - Disclosure - Stock Grants (Details Narrative) Sheet http://cardaxpharma.com/role/StockGrantsDetailsNarrative Stock Grants (Details Narrative) Details http://cardaxpharma.com/role/StockGrants 39 false false R40.htm 00000040 - Disclosure - Stock Option Plans (Details Narrative) Sheet http://cardaxpharma.com/role/StockOptionPlansDetailsNarrative Stock Option Plans (Details Narrative) Details http://cardaxpharma.com/role/StockOptionPlansTables 40 false false R41.htm 00000041 - Disclosure - Stock Option Plans - Schedule of Stock Option Activity (Details) Sheet http://cardaxpharma.com/role/StockOptionPlans-ScheduleOfStockOptionActivityDetails Stock Option Plans - Schedule of Stock Option Activity (Details) Details 41 false false R42.htm 00000042 - Disclosure - Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) Sheet http://cardaxpharma.com/role/StockOptionPlans-ScheduleOfNon-vestedSharesGrantedUnderStockOptionPlanDetails Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) Details 42 false false R43.htm 00000043 - Disclosure - Stock Option Plans - Schedule of Fair Value Assumptions (Details) Sheet http://cardaxpharma.com/role/StockOptionPlans-ScheduleOfFairValueAssumptionsDetails Stock Option Plans - Schedule of Fair Value Assumptions (Details) Details 43 false false R44.htm 00000044 - Disclosure - Stock Option Plans - Schedule of Recognized Stock Based Compensation Expense (Details) Sheet http://cardaxpharma.com/role/StockOptionPlans-ScheduleOfRecognizedStockBasedCompensationExpenseDetails Stock Option Plans - Schedule of Recognized Stock Based Compensation Expense (Details) Details 44 false false R45.htm 00000045 - Disclosure - Warrants (Details Narrative) Sheet http://cardaxpharma.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://cardaxpharma.com/role/WarrantsTables 45 false false R46.htm 00000046 - Disclosure - Warrants - Schedule of Stock Warrants Activity (Details) Sheet http://cardaxpharma.com/role/Warrants-ScheduleOfStockWarrantsActivityDetails Warrants - Schedule of Stock Warrants Activity (Details) Details 46 false false R47.htm 00000047 - Disclosure - Income Taxes (Details Narrative) Sheet http://cardaxpharma.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://cardaxpharma.com/role/IncomeTaxes 47 false false R48.htm 00000048 - Disclosure - Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Income (Loss) (Details) Sheet http://cardaxpharma.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfBasicAndDilutedNetIncomeLossDetails Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Income (Loss) (Details) Details 48 false false R49.htm 00000049 - Disclosure - Basic and Diluted Net Loss Per Share - Schedule of Computation of Diluted Net Income (Loss) Per Share (Details) Sheet http://cardaxpharma.com/role/BasicAndDilutedNetLossPerShare-ScheduleOfComputationOfDilutedNetIncomeLossPerShareDetails Basic and Diluted Net Loss Per Share - Schedule of Computation of Diluted Net Income (Loss) Per Share (Details) Details 49 false false R50.htm 00000050 - Disclosure - Leases (Details Narrative) Sheet http://cardaxpharma.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://cardaxpharma.com/role/Leases 50 false false R51.htm 00000051 - Disclosure - Subsequent Events (Details Narrative) Sheet http://cardaxpharma.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://cardaxpharma.com/role/SubsequentEvents 51 false false All Reports Book All Reports cdxi-20180930.xml cdxi-20180930.xsd cdxi-20180930_cal.xml cdxi-20180930_def.xml cdxi-20180930_lab.xml cdxi-20180930_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 69 0001493152-18-015783-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-015783-xbrl.zip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�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end